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ABSTRACT
Amyloid hypothesis is widely accepted as the centerpiece of Alzheimer’s disease
(AD) pathogenesis. It is believed that the accumulation of amyloid beta (A) is
the major deterministic factor of AD and the most important causative factor is
the ratio of AAGamma()-secretase defines the length of A and is
composed of at least four subunits: presenilins (PS1 or PS2), nicastrin (NCT),
anterior pharynx-defective 1 (Aph-1), and presenilin enhancer 2 (Pen-2). They
have been reported to have different roles in -secretase. For example, PS were
believed as the catalytic components in -secretase; NCT was recognized as a
substrate receptor; Pen-2 was regarded as necessary for the endoproteolysis of
PS which necessary for the activity of PS; and Aph-1 was known as important for
stabilization of the other -secretase components. However, these notions having
been challenged by new and controversial findings, which make the functions of
these components remain elusive. Therefore, the goal of my research projects is
to address these controversial issues by systematically investigate the function of
these components in -secretase activity and in apoptosis.
Our results demonstrate that 1) Aph-1 is dispensable for -secretase catalyzed
processing of both Notch and amyloid beta precursor protein (APP); 2) NCT is
crucial for APP processing, but is not absolutely required for Notch processing;
3) Pen-2 is necessary for the processing of both Notch and APP processing;
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4) Pen-2 is the most important component for recruiting substrates; 5) Knockout
of Aph-1 sensitizes cells to apoptosis; 6), PS1 accounts for the majority of the secretase activity the PS1C299 (from amino acid 299 to the end amino acid 467)
is the most active form of PS1 C. These new findings not only significantly
contribute to our knowledge of the biochemistry of -secretase and its catalyzed
Notch and APP processing, but also provide valuable information for the
development of therapeutic strategy of prevention and treatment of AD.
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INTRODUCTION
Alzheimers’ Disease
Dementia is a common brain disease, especially among aged people, from which
not only patients but also their families deeply suffer. Among all kinds of
dementia, about 50% to 70% are Alzheimer’s disease (AD). It has been more
than 100 years since the description of the first AD case by the Germen
psychiatrist Alois Alzheimer. However, there is still no cure available for
treatment of this devastating disease. AD is a neurodegenerative disease which
is clinically characterized by memory loss, inability of carrying conversation,
impaired judgement, difficulty of recognizing people and eventually death
(Alzheimer's 2013). As a progressive disease, it takes several years to develop
which is emotionally, physiologically and financially consuming.
Although age is recognized as the major risk factor of AD, AD is not a normal
part of aging and more than 5 percent of AD patients have earlier onset (younger
than 60). AD ranks as the sixth death cause in United States (Sherry et.al 2013),
and even worse, the death caused by AD increase by 68% between 2000 and
2010, while the death caused by other listed disease decreased (Arialdi et al
2002 and Sherry et.al 2013). With the globally population ageing, AD will become
a severe threaten with increasing shadows to people and our society.
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Molecular Mechanism of AD
Amyloid  Ahypothesis
AD is pathologically characterized by the presence of extracellular plaques
enriched in amyloid-beta (Aβ) peptides and intracellular neurofibrillary tangles
containing hyperphosphorylated tau protein (Selkoe 1998). Mounting evidence
suggests that the abnormal accumulation of Aβ is not only a hallmark of AD, but
is a primary causative factor of AD, and this theory is known as amyloid
hypothesis (Hardy and Selkoe 2002). Based on this hypothesis, it is believed that
the accumulation of Ais the direct cause of AD, although, the amyloid
hypothesis has and still does confront lots of doubts and rejections (Herrup
2015). Another hallmark of AD is intracellular neurofibrillary tangles (NTFs),
which are composed of phosphorylated tau protein. Together with extracellular
plaque, NTFs were found in AD patient’s brain. Researchers have found that
both NTFs and plaques could result in neuron loss which contributes dramatically
to AD. However, compare to AaggregationNTFs is not the predominant one.
Since the tangle formation could be influenced by both Aand APP, but the
plaque formation is barely affected by tau overexpression, A is suggested to be
the primary and deterministic factor of AD (Lewis, Dickson et al. 2001).
Preclinical studies also support amyloid cascade hypothesis since
Aimmunotherapies could help in preventing AD (Lemere and Masliah 2010).
Therefore, amyloid cascade hypothesis is still the most widely accepted one in
AD physiology.
2

APP processing and Aβproduction
Aβ is produced from the amyloid precursor protein (APP). APP is a type I single
transmembrane protein which could be processed in two different pathways:
amyloidogenic pathway and non-amyloidogenic pathway. In these pathways,
APP is first cleaved by -secretase or -secretase and produce C terminal
fragments, CTFor CTFrespectively. The CTFand CTFwill be
subsequently processed by -secretase into Aand p3, respectively and,
concomitantly, a common APP intracellular C terminal domain (AICD) (Figure I)
(Xu 2009). In fact, the first disease causative gene identified is the APP gene.
The other two are Presenilin1 (PS1) and Presenilin 2 (PS2) genes. PS1 and PS2
are two proteins sharing high homology with each other. Mutations in these two
presenilin genes account for the majority of familial Alzheimer’s Disease (FAD)
cases (De Strooper 2007). Interestingly, the mutations in all the disease
causative genes, APP, PS1 and PS2, lead to one common consequence: the
increased production of ABased on the accumulation of knowledge and
evidences, amyloid cascade hypothesis was first summarized at the 1992 by Dr.
Hardy and Dr. Higgins (Hardy and Higgins 1992). They suggest that the
accumulation of Ais the direct cause of AD.
BACE
As mentioned above, A is produced from APP through sequential cleavage of
secretase and secretase. secretase, also known as BACE (Beta Site
3

APP-Cleaving Enzyme) (Vassar, Bennett et al. 1999) has two homologues:
BACE1 and BACE2, among which BACE1 has the major activity at processing
APP and producing CTFwhich could be further processed into A (Farzan,
Schnitzler et al. 2000, Basi, Frigon et al. 2003). BACE1 is confirmed of required
for production of A through knock out experiments in mice (Cai, Golde et al.
1993). The knockout of BACE in mice also cause dramatic neonatal lethality
(Dominguez, Tournoy et al. 2005), which suggests that BACE is significantly
necessary for some other functions in vivo. This critical role of BACE in the
development leads to the difficulties of targeting it for the treatment of AD.

secretase components
Further researches discovered that the ratio of Aβ42 versus Aβ40 (Aβ42/Aβ40) is
critical for AD development (Hardy and Selkoe 2002, Kumar-Singh, Theuns et al.
2006). The secretase controls the length of A. Therefore, secretase has
come under the spotlight of AD research and for the understanding of
mechanism of Aproduction and AD treatment. secretase is composed of at
least four components: presenilins (PS1 or PS2), nicastrin (NCT), anterior
pharynx-defective 1 (Aph-1), and presenilin enhancer 2 (Pen-2)
Among those, the nine transmembrane protein presenilin (PS1 or PS2 isoforms)
is thought to be the catalytic subunit, since the mutation of the two aspartyl
residues results in the loss of secretase activity (Wolfe, Xia et al. 1999, Wolfe
2002). NCT is suggested to be substrate receptor (Shah, Lee et al. 2005). A
more recent research suggests NCT acts as a molecular gatekeeper for
4

substrate binding and catalysis through actively excludes larger substrates with
steric hindrance (Bolduc, Montagna et al. 2016). Aph-1 might be required for the
stabilization of other secretase components (Francis, McGrath et al. 2002, Lee,
Shah et al. 2002, Steiner, Winkler et al. 2002). Pen-2 was believed to be required
for the endoproteolysis of presenilin which is a necessary step in secretase
maturation (Luo, Wang et al. 2003, Takasugi 2003). However, recent researches
have raised questions to this notion, for example Pen-2 is only partially required
for endoproteolysis of presenilin as demonstrated by recent studies (Mao, Cui et
al. 2012, Holmes, Paturi et al. 2014) and NCT is not absolutely required for the
processing of Notch which is one of secretase substrate (Zhao, Liu et al. 2010).
These controversial results casted shadows over the current view regarding the
functional role of each component in secretase complex. In addition, the
catalytic functions of PS1 and PS2 have been well defined, however, the
mechanisms remain elusive. Therefore, we set out to address these issues by
the following proposed study.

secretase substrates
As discussed above, based on Amyloid hypothesis, one way for the treating AD
is to inhibit secretase activity in order to reduce the production of Aβ. However,
more than 90 type I transmembrane proteins have been identified as secretase
substrates (Haapasalo and Kovacs 2011), including APP (De Strooper, Saftig et
al. 1998), Notch (De Strooper, Annaert et al. 1999), E-cadherin, N-cadherin,
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ErbB4 and so on. Specifically, secretase catalyzed Notch processing plays an
important role in controlling cellular homeostasis and cell fate determination.
Thus, it becomes difficult to simply inhibit secretase activity as a therapeutic
strategy for treating AD. Notch pathway requires the processing of secretase to
produce a Notch intracellular domain (NICD) in order to regulate the transcription
of important genes for cell development, proliferation, differentiation and so on
(Kopan and Ilagan 2009, Andersson, Sandberg et al. 2011). Thus, the inhibition
of secretase will result in other severe consequences through failure of Notch
signaling regulation. Therefore, it becomes important to find a way to selectively
inhibit secretase catalyzed APP processing without affecting the Notch
processing, which is one of the goals of my research project.

Apoptosis in AD
The importance of apoptosis in AD has been discussed in 1998 by Marcia
Barinaga (Barinaga 1998), in which they speculate that apoptosis could play a
role in neuron death found in AD. Since then, scientists found more evidence to
support this idea. The anti-apoptotic protein level Bcl2 was found lower in AD
brain, the active forms of caspase 3 was detected and so does the fragmentation
of DNA (Shimohama 2000). In vitro experiments have also demonstrated that
expression of Aβ could induce the activation of caspases (Ivins, Thornton et al.
1999). Lots of signaling pathway, like JNK (Troy, Rabacchi et al. 2001), GSK3β
(Lucas, Hernandez et al. 2001), even PS1 (Soriano, Kang et al. 2001) itself have
been reported of involving in the apoptosis of AD (Bamberger and Landreth
6

2002). Besides PS1, some other secretase components, like Aph-1 and Pen-2
have been found contribute to apoptosis as protective roles through p53 pathway
due to the fact that they could help in keeping the integrity of secretase
complex (Dunys, Kawarai et al. 2007). Since we have different secretase
components knock out cells, alongside with investigations about their roles in
secretase activity, we also studies their role in apoptosis. Our result
demonstrates that the knock out Aph-1 lead to higher tendency of apoptosis in
mouse embryonic fibroblast (MEF) cells when triggered by MG132 through AktGSK3β pathway. Combined with the results of secretase activity: Aph-1 is not
definitely required for the processing of both Notch and APP, but more
importantly for the stability of secretase and cell survival (Hu, Zeng et al. 2015).
Therefore, the targeting of Aph-1 in treating AD is completely unreasonable
theoretically.

Therapy
Several anti-Aβ monoclonal antibodies like Bapineuzumab and crenezumab were
tested in clinical trials. They have been demonstrated to have no significant effect
on cognition but only decrease some level of aggregated Aβ or soluble Aβ
(Doody, Thomas et al. 2014, Salloway, Sperling et al. 2014). Some β-secretase
inhibitors are under test at the clinical trial phase 2 or 3. They have been found to
be able to reduce 80% production of Aβ, but the effects on cognition and
prevention of AD need to be further determined (Ayutyanont, Langbaum et al.
7

2014) (Bateman 2015). Lots of secretase inhibitors (GSI) and secretase
modulators (GSM) are at phase 2 or 3 stage of clinical trials, but most of them
are either not efficient or have significant side effects and toxicity since including
Notch, plenty of secretase substrates and their pathways are influenced
(Cummings 2010, Samson 2010, Schor 2011). When comparing with GSI, the
toxicity of GSM is much less since they only regulate the length of Aβ rather than
the activity of secretase. Since the longer forms of Aβ have been demonstrated
to be easier at aggregation and forming plaque (Xu 2009), if proper GSM which
could reduce the production of longer Aβ, that would be helpful in treat AD.
Alternatively, we might be able to switch to targeting secretase components,
for example NCT, since we have found that the knockout of NCT could
selectively inhibits APP processing, but has less effect on Notch processing (Hu,
Zeng et al. 2015). Hope our research on the structure and function of secretase
could provide further supports on the development of AD treatment.
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CHAPTER I
NICASTRIN IS REQUIRED FOR APP BUT NOT
NOTCH PROCESSING, WHILE APH-1 IS
DISPENSABLE FOR PROCESSING OF BOTH APP
AND NOTCH
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Abstract
The -secretase complex is composed of at least four components: presenilin
(PS1 or PS2), nicastrin (NCT), anterior pharynx-defective 1 (Aph-1), and
presenilin enhancer 2 (pen-2). In this study, using knockout cell lines, our data
demonstrated that knockout of NCT, as well as knockout of Pen-2, completely
blocked -secretase-catalyzed processing of CTFα and CTFβ, the C-terminal
fragments of β-amyloid precursor protein (APP) produced by α-secretase and βsecretase cleavages, respectively. Interestingly, in Aph-1-knockout cells CTFα
and CTFβ were still processed by -secretase, indicating Aph-1 is dispensable
for APP processing. Furthermore, our results indicate that Aph-1 as well as NCT
is not absolutely required for Notch processing, suggesting that NCT is
differentially required for APP and Notch processing. In addition, our data
revealed that components of the -secretase complex are also important for
proteasome- and lysosome-dependent degradation of APP and that endogenous
APP is mostly degraded by lysosome while exogenous APP is mainly degraded
by proteasome.

Introduction
One of the hallmarks of Alzheimer's disease (AD) is the abnormal production
and accumulation of β-amyloid peptide (Aβ) in the brain. According to the
amyloid hypothesis, the ratio of the long Aβ species, Aβ42, versus the short
Aβ40 (Aβ42/Aβ40) has been considered to play a critical role in AD (Hardy and
17

Selkoe 2002). An increased Aβ42/Aβ40 ratio appears to correlate with earlyonset familial AD cases caused by presenilin mutations (Kumar-Singh, Theuns et
al. 2006). Aβ is derived from the amyloid precursor protein (APP) by successive
action of the β- and -secretases. APP can be processed via two pathways, the
non-amyloidogenic pathway or the amyloidogenic pathway. In the nonamyloidogenic pathway, APP is first cleaved by -secretase to release a soluble
N-terminal ectodomain and a membrane anchored C-terminal fragment (CTF);
in the amyloidogenic pathway, APP is first cleaved by β-secretase to remove the
N-terminal fragment and generate a membrane-anchored C-terminal fragment of
APP (CTF). Both CTF and CTF are then subsequently cleaved within the
transmembrane domain by -secretase to produce a common APP intracellular
domain (AICD) and lead to the generation of a p3 fragment from CTF and the
full-length A from CTF (Xu 2009). Since the -secretase-catalyzed cleavage
determines the C-termini of A species and the ratio of Aβ42/Aβ40, dissecting
the biological and biochemical nature ofsecretase is important for
understanding the mechanism of Aβ formation. Thus far at least four
polypeptides have been identified as necessary components for -secretase
activity (Dries and Yu 2008, Zhang, Li et al. 2014). These four components are
presenilins (PS1 or PS2), nicastrin (NCT), anterior pharynx-defective 1 (Aph-1),
and presenilin enhancer 2 (Pen-2). Mutation of the two conserved aspartyl
residues in PS1 and PS2 results in the loss of -secretase activity (Wolfe 1999),
and affinity labeling experiments have demonstrate that -secretase inhibitors
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bind directly to PS1 (Esler, Kimberly et al. 2000, Li, Xu et al. 2000); therefore, the
nine transmembrane protein presenilin (PS1 or PS2 isoforms) is thought to
function as the catalytic subunit of -secretase (Wolfe 2002). The identification of
a substrate-binding domain in NCT strongly suggests that NCT functions as the
substrate receptor (Shah, Lee et al. 2005). Using siRNA technology, studies
suggested that the seven transmembrane protein Aph-1 is required for
stabilization of the PS1 endoproteolysis products PS1N and PS1C (Francis,
McGrath et al. 2002, Lee, Shah et al. 2002, Steiner, Winkler et al. 2002) and that
the two transmembrane protein Pen-2 is required for endoproteolysis of PS1
(Luo, Wang et al. 2003, Takasugi, Tomita et al. 2003). However, recent studies
have shown that Pen-2 is dispensable for endoproteolysis of PS1 (Mao, Cui et al.
2012, Holmes, Paturi et al. 2014). One study also showed that NCT is not
absolutely required for -secretase activity (Zhao, Liu et al. 2010). To further
determine the role of each component of the -secretase complex in -secretase
activity, we used knockout cell lines to examine the effect of deletion of each
component on the processing of CTFα and CTFβ. Our data demonstrated that
knockout of Pen-2, as well as NCT, almost completely blocked the processing of
both CTFα and CTFβ. However, knockout of Aph-1 had no significant effect on
the processing of CTFα and CTFβ, indicating Aph-1 is dispensable for APP
processing. Furthermore, our results revealed that NCT is differentially required
for -secretase-catalyzed processing of APP and Notch. In addition, our data
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suggest that the components essential for -secretase-dependent APP
processing are also important for APP degradation.

Materials and Methods
Cell culture
Mouse embryonic fibroblast (MEF) cells established from PS1/PS2-double
knockout (PS1/2-/-) cells (Herreman, Serneels et al. 2000), PS1-knockout (PS1-/-)
cells (De Strooper, Saftig et al. 1998), PS2-knockout (PS2-/-) cells (Herreman,
Hartmann et al. 1999), Pen-2-Knockout (Pen-2-/-) cells (Bammens, ChavezGutierrez et al. 2011), and wild-type mouse embryonic fibroblasts were all kindly
provided by Dr. Bart De Strooper (Center for Human Genetics, Belgium).
Nicastrin-knockout (NCT-/-) cells (Li, Ma et al. 2003) and Aph-1abc-triple-deficient
(Aph-1-/-, deficient in all three Aph-1a, Aph-1b, and Aph-1c isoforms) cells
(Chiang, Fortna et al. 2012) were kindly provided by Dr. Tong Li (John Hopkins
University). The wt-7 cells (N2a cells stably expressing wild-type presenilin 1
[PS1wt] along with Swedish mutant APP [APPsw]) were kindly provided by Drs.
Sangram S. Sisodia and Seong- Hun Kim (University of Chicago). All cells were
cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine
serum, 2 mM L-glutamine (Lonza, Walkersville, MA, USA), 100 units/mL penicillin
(Lonza), and 100 μg/mL streptomycin (Lonza).
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Inhibitors and reagents
Proteasome inhibitor MG132 was purchased from Peptides International
(Louisville, KY, USA). Gamma-secretase inhibitors compound E and L685, 458
and proteasome inhibitor lactacystin were purchased from EMD Millipore
(Billerica, MA, USA). Lysosome inhibitors chloroquine, leupeptin, and NH4Cl were
purchased from Sigma (St. Louis, MO, USA). The general caspase inhibitor,
benzyloxycarbonyl-Val- Ala-Asp-fluoromethylketone (Z-VAD-fmk) was purchased
from Enzo Life Sciences (Farmingdale, NY, USA). Complete protease inhibitor
cocktail tablets were purchased from Roche Applied Science (Indianapolis, IN,
USA). Lipofectamine LTX with plus reagent was purchased from Invitrogen
(Carlsbad, CA, USA).
Antibodies
Anti-PS1C, anti-NICD (#4147, which specifically recognizes the processed
Notch), anti-caspase3, and anti-caspase-6 were purchased from Cell Signaling
(Danvers, MA). Anti-NCT was from Sigma-Aldrich (St. Louis, MO, USA).
Polyclonal antibodies anti-Aph-1aL and anti-PEN-2N were from Covance
(Princeton, NJ, USA). Anti-Aph-1bc was from NOVUS (Littleton, CO, USA).
Polycolonal antibody C15 was raised against the last 15 amino acids at the very
C terminal of APP (Zhao, Mao et al. 2004). Anti-myc antibody, C-Myc (9E10),
was purchased from Santa Cruz (Dallas, TX, USA). Anti-GAPDH (glyceraldehyde
3-phosphate dehydrogenase) was from EMD Millipore.
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Plasmids
Plasmid expressing the truncated ectodomain and myc-tagged Notch molecule
(NotchΔE) containing the murine Notch-1 leader peptide (1-23 amino acids)
(Kopan, Schroeter et al. 1996) was kindly provided by Dr. Raphael Kopan
(Washington University) and Dr. Masayasu Okochi (Osaka University, Japan).
The plasmid APPsw, which expresses a C-terminal myc-tagged Swedish mutant
APP (APPsw) (Thinakaran, Teplow et al. 1996), was kindly provided by Dr.
Gopal Thinakaran (University of Chicago).
Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR was carried out as described previously (Hao, Tan et al. 2010). Total
RNA was isolated from MEF cells mentioned above using an RNeasy mini-prep
kit (Qiagen, Hilden, Germany). cDNA was synthesized from 2 μg total RNA using
the ThermoScipt RT-PCR kit (Invitrogen). The cDNA products were amplified
using GeneAmp PCR core reagents (Applied Biosystems, Foster City, CA, USA)
and a Stratagene Mx3000P thermocycler (Agilent, Santa Clara, CA, USA) with
the following program: 5 min at 95°C followed by 28 cycles of denaturing at 95°C
for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 45 s followed by a
final extension for 7 min at 72°C. The primers used were as follows: Aph-1a,
forward 5′-ACGGAAGATCACCCAT-3′ and reverse 5′TGTCAGAAGGTGACTCCCA-3′; Aph-1b,c, forward 5′CCTGACGCATCTGGTGGTG-3′ and reverse 5′-GTTCCAAGATACAGGGG-3′;
and NCT, forward 5′-TCTTCTCACACATGCACGCC-3′ and reverse 5′22

CATGGGATCTGTGTGCATCC-3′. The PCR products were analyzed by
electrophoresis on a 2% agarose gel.
Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed as described previously (Tan, Mao et al. 2008, Zhao, Liu
et al. 2010). MEF cells were cultured for 24 h. Conditioned media (CM) were
supplemented with an inhibitor cocktail (Millipore) containing AEBSF (4-[2aminoethyl] benzenesulfonyl fluoride hydrochloride) at a final concentration of 1
mM. The CMs were analyzed with a mouse Aβ40according to the manufacturer’s instructions.
Cell-free assay
In vitro AICD (APP intracellular domain) generation was determined by cell-free
assay using the protocol reported by Tesco et al (Tesco, Ginestroni et al. 2005).
MEF cells were grown at a density of 150,000 cells/cm2 for 24 h. Cells were
scraped in 1 ml buffer A (50 mM HEPES, 150 mM NaCl, 5 mM 1,10phenanthroline monohydrate [PNT], pH=7.4) and homogenized by passing them
through 25-gauge 5/8 needles 10 times. The homogenate was centrifuged at
10,000 × g for 15 min at 4°C. The membrane fraction obtained was washed once
with buffer A and centrifuged at 10,000 × g for 5 min at 4℃. Total protein was
measured in the membrane fraction, and protein aliquots were incubated with 50
µl buffer B (50 mM HEPES, 150 mM NaCl, 5 mM PNT, cocktail protease
inhibitor, chloroquine (10 μM), pH=7.0) for 2 h at 37°C in the presence or
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absence of L685, 458 to induce the production of AICD. After incubation,
samples were centrifuged at 10,000 × g for 15 min at 4°C. The supernatants
were collected and analyzed by Western blot using anti-APP-CTF antibody, C15.
SDS-PAGE and Western blotting
For analysis of endogenous APP processing, 10 h after splitting, cells were
incubated overnight in the presence or absence of the following inhibitors
compound E (5nM), L685, 458 (0.5 μM), lactacystin (10 μM), MG132 (5uM),
chloroquine (10 μM), leupeptin (5 μg/ml), and NH4Cl (1mM). For analysis of the
exogenous APP and Notch processing, the cells, 24 h after splitting, were
transfected with plasmids expressing APPsw or NotchΔE with lipofectamine LTX.
Ten hours after transfection, inhibitors were added and the cells were further
incubated overnight. Cell lysis and Western blot analysis were carried out as
described previously (Zhao, Mao et al. 2004). Briefly, cells were lysed with
sonication for 20 s on ice in Western blot lysis buffer (50 mM Tris–HCl, pH 6.8,
8 M urea, 5% mercaptoethanol, 2% SDS, and protease inhibitor mixture). After
addition of 4 × SDS sample buffer and boiling at 100°C for 7 min, samples were
subjected to SDS-polyacrylamide gel electrophoresis (SDS PAGE, 16% for APP
CTFs; 14% for PS1 C terminals, caspases, and GAPDH; 10% for Notch and CNotch; 6% for APP). The membranes were probed with appropriate antibodies as
described in figure legends.
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Statistical analysis
Data are expressed as mean ± SEM and assessed for significance by Student's t
test. When P > 0.05, differences were considered not significant.
All methods used are approved by University of Tennessee (Registration #30913).

Results
Aph-1 is dispensable for -secretase-catalyzed processing of CTF
To determine the role of the components of the -secretase complex in APP
processing activity, we examined the effects of deletion of each component of the
complex on the processing of CTF. As shown in Figure 1. 1a, as expected, in
the absence of inhibitor, almost no CTF was detectable in wild type (wt) cells
(lane 9). However, when the cells were treated with transition state -secretase
inhibitor L-685,458, a significant amount of unprocessed CTF was accumulated
(lane 10). As reported previously (Herreman, Serneels et al. 2000), a dramatic
accumulation of unprocessed CTF was observed in the PS1 and PS2 double
knockout (PS1/2-/-) cells (compare lanes 13 and 14) regardless of the presence
or absence of -secretase inhibitor. Similarly, significant accumulation of CTF
was also observed in nicastrin-knockout (NCT-/-) cells (lanes 3 and 4) and Pen-2knockout (Pen-2-/-) cells (lanes 5 and 6) regardless of the presence or absence of
-secretase inhibitor.
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However, in contrast to knockout of NCT or Pen-2, a significant decrease in
the level of CTF was detected in the Aph-1-knockout (Aph-1-/-) cells in which all
three murine Aph-1 alleles–termed Aph-1a, Aph-1b, and Aph-1c–were knocked
out (Figure 1. 1a, lane 1). More interestingly, the decrease in the level of CTF
was completely blocked by -secretase inhibitor (lane 2). In addition, we also
observed that knockout of PS2 had almost no effect on the turnover of CTFα
(lane 11) and this decrease in CTFα in PS2-knockout (PS2-/-) cells was
completely inhibited by -secretase inhibitor (lane 12). This result indicates that
knockout of PS2 did not cause significant reduction in -secretase activity.
However, a significant amount of CTFα was detected in the PS1-knockout (PS1-/) cells in the absence of inhibitor (lane 7), indicating a substantial reduction in secretase activity.
Previous studies have reported that CTFs of APP undergo degradation by a
proteasome-dependent mechanism distinct from -secretase (Skovronsky, Pijak
et al. 2000, Nunan, Shearman et al. 2001, Nunan, Williamson et al. 2003). To
determine whether the decrease of CTF detected in the Aph-1-knockout cells is
indeed due to -secretase, we examined the effect of proteasome inhibitor on the
turnover of CTFAs shown in Figure 1. 1b, treatment of cells with proteasome
inhibitor MG132 caused a slight increase in the level of CTF in Aph-1-1- cells
(compare lane 2 with lane 1). A similar result was also observed in PS1-knockout
cells (compare lane 8 with lane 7) and wt cells (compare lane 14 with lane 13).
However, the extent of the increase in CTF caused by MG132 is much less
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than that caused by -secretase inhibitor (compare Figure 1. 1b with 1a). These
results indicate that, similar to wt cells, the turnover of CTF in the Aph-1-/- cells
is mainly catalyzed by -secretase activity. In addition, MG132 showed no
significant effect on the level of CTF in NCT-/- cells (compare lanes 4 with lane
3), Pen-2-/- cells (compare lane 6 with lane 5), nor PS1/2-/- cells (compare lane 12
with lane 11). It was noted that no CTFβ was detected in these experiments,
suggesting a possibility that the mouse endogenous APP was mostly processed
via the α-secretase pathway and that the low level of CTFβ was undetectable
under our experimental conditions.
If the turnover of CTFα in Aph-1-/- cells were catalyzed by -secretase activity
rather than by random degradation, the AICD produced by -secretase activity
would be detectable. However, AICD was not detected in the experiments shown
in Figure 1. 1a and b, possibly due to rapid degradation of this peptide in living
cells [Cupers, 2001 #7150]. Thus, we performed a cell-free assay using the
procedure described previously (Tesco, Ginestroni et al. 2005). As shown in
Figure 1. 1c, in the absence of -secretase inhibitor, a significant amount of AICD
was readily detected in membrane prepared from wt (lane 5), Aph-1-/- (lane 7),
and PS2-/- (lane 9) cells, and the generation of AICD in these cells was strongly
inhibited by -secretase inhibitor L-685,458 (lanes 6, 8, and 10). Similarly, in wt-7
cells, both AICD-myc and AICDendo, produced from exogenous APP with a myctag and endogenous APP, respectively, were detected at very high levels (lane
15) and inhibited by L-685,458 (lane 16). However, this AICD was not detected in
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NCT-/-, Pen-2-/-, and PS1/2-/- cells regardless of the presence or absence of secretase inhibitor (lanes 1 to 4, and lanes 13 and 14). These results strongly
indicate that the turnover of CTFα in Aph-/- cells is catalyzed by -secretase
activity. AICD was hardly detected in PS1-/- cells (lanes 11 and 12), suggesting
that PS1 accounts for the majority of the -secretase activity. To further ascertain
whether APP is indeed processed by -secretase in Aph-1-/- cells, we performed
an ELISA to determine the formation of Aβ in these cells. As shown in Figure 1.
1d, a large amount of Aβ40 was detected in the media of wt and PS2-/- cells.
Interestingly, a significant amount of Aβ40 (> 50% of that detected in wt cells) was
also detected in Aph-1-/- cells when PS1/2-/- cells were used as a negative
control. This result provided further strong support to the notion that APP is
indeed processed by -secretase activity in Aph-1-/- cells. On the other hand, only
a low, but still significant, level of Aβ40 (< 20% of that detected in wt cells) was
detected in PS1-/- cells, and a very low level of Aβ40 (< 8% of that detected in wt
cells) was also detected in NCT-/- and Pen-2-/- cells.
Aph-1c protein is undetectable in Aph-1abc-triple deficient cells under the
experimental conditions
Since the Aph-1-/- cells were created by knockdown of Aph-1c in Aph-1a/b
double knockout cells using shRNA technology (Chiang, Fortna et al. 2012), one
concern is whether the -secretase activity detected in Aph-1-/- cells results from
incomplete knockdown of Aph-1c. To address this issue, we performed a RTPCR assay to determine the mRNA level of Aph-1c using primers corresponding
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to the coding regions of Aph-1c. As controls, similar RT-PCR was also performed
for Aph-1a and NCT. As shown in Figure 1. 1e, as expected, neither NCT mRNA
nor Aph-1a mRNA was detected in NCT-/- and Aph-1-/- cells, respectively.
However, as shown in the second panel of Figure 1. 1e, a fine PCR band was
detected in Aph-1-/- cells, indicating the presence of a trace amount of residual or
partially cleaved Aph-1c mRNA in Aph-1-/- cells. Thus, we further determined the
protein levels of Aph-1c and other components in these knockout cells used. As
shown in Figure 1. 1f, Western blot analysis using specific antibodies confirmed
the absence of PS1, PS2, NCT, and Pen-2 as well as Aph-1 (Aph-1a, Aph-1b,
and Aph-1c) proteins in the corresponding knockout cells. Specifically, the fact
that antibody specific to Aph-1b/c did not detect any signal in Aph-1-/- cells
suggests that the Aph-1c gene was efficiently silenced by shRNA technology.
Components of the -secretase complex might also play a role in regulating
APP CTF degradation by proteasome and lysosome.
It was noted from the above experiments that treatment with proteasome inhibitor
MG132 caused an increase in the level of CTF in wt, Aph-1-/-, and PS1-/- cells.
However, MG132 showed no effect on the level of CTF in NCT-/-, Pen-2-/-, and
PS1/2-/- cells. These results suggest that knockout of different components might
have different effects on the proteasome-dependent turnover of CTFα. APP and
its processing products have also been reported to be subjected to lysosome
degradation (Eisele, Baumann et al. 2007, Vingtdeux, Hamdane et al. 2007).
Thus, next, we examined the effects of other proteasome and lysosome inhibitors
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on the turnover of CTFα in these knockout cells. As shown in lanes 2 and 3 of the
top four panels of Figure 1. 2a, as expected, both of the -secretase inhibitors,
compound E (compE) and L-685,458, caused accumulation of unprocessed
CTFα in wt, PS1-/-, PS2-/-, and Aph-1-/- cells. When the cells were treated with
proteasome inhibitors MG132, strong accumulation of CTFα resulted in wt, PS1 -/, and Aph-1-/- cells (lane 5), but lactacystin in comparison, caused a lesser
accumulation of CTFα in PS1-/- and Aph-1-/- cells (lane 4), and CTFα was hardly
detectable in wt cells (lane 4). Neither MG132 nor lactacystin had a detectable
effect on the CTFα level in PS2-/- cells (Panel 3, lanes 4 and 5). When the cells
were treated with the lysosome inhibitors chloroquine, leupeptin, and NH4Cl,
significant accumulation of CTFα was observed in wt, PS1-/-, PS2-/-, and Aph-1-/cells. In addition, it was noted that in the presence of lysosome inhibitors,
specifically, chloroquine and leupeptin, the APP intracellular c-terminal domain
(AICD) produced by -cleavage of CTFα become detectable in wt cells, PS2-/cells, and to a lesser extent in Aph-1-/- cells. These results suggest that lysosome
is the major site for CTFα degradation. In addition, the detection of AICD in the
presence of lysosome inhibitors indicates that these lysosome inhibitors have no
effect on -secretase catalyzed processing of CTFα. As shown in the bottom
three panels of Figure 1. 2a, the proteasome inhibitors lactacystin and MG132
had no effect on the level of CTFα in PS1/2-/-, NCT-/-, and Pen-2-/- cells.
Lysosome inhibitors caused a slight increase in the level of CTFα in these cells.
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These results indicate that CTFα was not significantly degraded by either
proteasome or lysosome activity in these cells.
As mentioned above, possibly because mouse endogenous APP was mostly
processed via the α-secretase pathway, the level of endogenous CTFβ was too
low to be detected under our experimental conditions. To determine the effects of
knockout of each -secretase component on the processing of CTFβ, we
transiently transfected these cells with a plasmid expressing myc-tagged human
Swedish mutant APP (APPsw) in the presence or absence of different inhibitors.
As shown in Figure 1. 2b, recombinant APP was detected in all transfected cells.
As shown in the top panel, in the wild type-cells, endogenous CTFα
(CTFα[endo]) as well as CTFα-myc and CTFβ-myc produced from exogenous
myc-tagged APPsw, were accumulated in the presence of the -secretase
inhibitors compound E (lane 4) and L-685,458 (lane 5). Similarly, -secretase
inhibitors caused accumulation of unprocessed CTFα-myc, and CTFα(endo) was
also clearly detected in Aph-1-/-, PS2-/-, and PS1-/- cells. These results indicate
that -secretase inhibitors had similar effects on both exogenous and
endogenous APP in these cells, excepting that CTFβ-myc was hardly detected in
these cells. In wt cells, the accumulation of CTFα(endo), CTFβ-myc, and CTFαmyc was also detected when cells were treated with the lysosome inhibitors
chloroquine and leupeptin, and to a lesser extent with NH4Cl (lanes 8–10).
However, mainly CTFα-myc and CTFβ-myc, but almost no CTFα(endo), were
accumulated in the presence of proteasome inhibitors lactacystin (lane 6) and
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MG132 (lane 7). In PS1-/-, PS2-/-, and Aph-1-/- cells, both CTFα(endo) and CTFαmyc were detected at various levels in the presence of these proteasome and
lysosome inhibitors. However, almost no CTFβ-myc was detected in these cells,
with the exception of MG132-treated Aph-1-/- cells (fourth panel, lane 7). A small
amount of CTFα-myc was detected in PS1-/- cells in the absence of any inhibitors
(second panel, lane 3), indicating a low -secretase activity in these cells in
comparison with that in PS2-/- cells.
It was interestingly noted that in PS1-/-, PS2-/-, and Aph-1-/- cells, treatment
with proteasome inhibitors lactacystin and MG132 mainly caused accumulation
of CTFα-myc (Figure 1. 2b, lanes 6 and 7), whereas lysosome inhibitors mostly
caused accumulation of CTFα(endo) (lanes 8–10). These data revealed an
interesting finding that exogenous APP was primarily degraded by proteasome,
and the endogenous APP was mostly degraded by lysosome. This notion was
further supported by the fact that exogenous full-length APP (both mature and
immature forms) was detected at high levels in the presence of proteasome
inhibitors in all cells (lanes 6 and 7). In contrast to the PS1-/-, PS2-/-, and Aph-1-/cells, neither proteasome nor lysosome inhibitors had a significant effect on the
levels of CTFα(endo) and CTFα-myc in PS1/2-/- cells (fifth panel), NCT-/- cells
(sixth panel), nor Pen-2-/- cells (seventh panel), indicating that APP CTFs were
not significantly degraded by these organelles in these cells. A small amount of
CTFβ-myc was also detected in these cells, specifically in cells treated with
MG132 and lysosome inhibitors (lanes 7–10). The above results clearly indicate
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that the effects of proteasome and lysosome on the turnover of full-length APP
and APP CTFs vary in different knockout cells.

-secretase-catalyzed CTFprocessing in Aph-1-/- cells is independent of
proteasome and lysosome activity
Data presented in Figure 1. 2a show that AICD was detected in Aph-1-/- cells as
well as in wt and PS2-/- cells in the presence of lysosome inhibitors, indicating
that -secretase activity was not affected by these lysosome inhibitors. In other
words, -secretase-catalyzed processing of CTFα is independent of lysosome
activity in these cells. To further determine whether the -secretase inhibitors
compound E and L-685,458 caused accumulation of CTFα in Aph-1-/- cells was
not due to inhibition of proteasome or lysosome activity, we performed the
following experiments. As shown in Figure 1. 3a, the amount of CTFα
accumulated in cells treated with both compound E and MG132 (lane 7) was
roughly the sum of the CTFα detected in cells treated with compound E (lane 2)
and MG132 (lane 4), separately. A similar result was also observed when L685,458 was used in combination with MG132 compared with L-685,458 and
MG132 alone (compare lane 9 with lanes 3 and 4). During the course of the
experiments, it was noted that treatment with MG132 could induce the activation
of caspase, which has been implied in the turnover of APP CTFs (Weidemann,
Paliga et al. 1999). This raised the question as to whether inhibition of caspase
activation would lead to further accumulation of CTFα in cells treated with
MG132. Indeed, a greater amount of CTFα was observed in MG132-treated cells
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in the presence of pan caspase inhibitor Z-VAD (compare lane 6 with lane 4).
When these cells were further treated with compound E, an even greater amount
of CTFα was accumulated (compare lane 8 with lane 6). A similar result was also
observed when L-685,458 was added with MG132 and Z-VAD (compare lane 10
with lane 6). These results indicate that -secretase inhibitor and proteasome
inhibitor have an additive effect on the accumulation of unprocessed CTFα
through different mechanisms. Furthermore, it was noted that in addition to
regular PS1C produced by normal endoproteolytic processing of PS1, a short Cterminal fragment of PS1, CaspPS1C, which was produced by caspase activity
(Zeng, Hu et al. 2015), was detected in cells treated with MG132 (lanes 4, 7, and
9), and the formation of CaspPS1C was completely inhibited by the addition of
pan caspase inhibitor Z-VAD (lanes 6, 8, and 10).
Next, we examined the additive effect of -secretase inhibitors and lysosome
inhibitors on the accumulation of unprocessed CTFα. As shown in Figure 1. 3b,
the amount of CTFα accumulated in the cells treated with both compound E and
chloroquine (lane 6) was roughly the sum of the CTFα detected in cells treated
with compound E (lane 2) and chloroquine (lane 4), separately. A similar result
was also observed when cells were treated with L-685,458 and chloroquine
(compare lane 7 with lanes 3 and 4). Likewise, leupeptin exhibited a similar
additive effect on CTFα accumulation when used in combination with compound
E (compare lane 8 with lanes 2 and 5) and L685, 458 (compare lane 9 with lanes
3 and 5). These data indicate that -secretase inhibitor-caused accumulation of
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CTFα in Aph-1-/- cells is not due to inhibition of proteasome or lysosome, i. e., secretase-catalyzed CTFα processing in Aph-1-/- cells is independent of
proteasome and lysosome activity.
Aph-1, as well as nicastrin is, dispensable for -secretase-catalyzed
processing of Notch
Data presented above demonstrate that Aph-1 is not absolutely required for secretase-catalyzed APP CTF processing, while NCT and Pen-2 are crucially
essential for this process. In addition to APP, Notch is another well-characterized
substrate of -secretase. We next examined the effect of knockout of different
components of the -secretase complex on the processing of Notch. To do so,
cells were transfected with a plasmid expressing NotchΔE, the ectodomaintruncated and myc-tagged Notch containing the murine Notch-1 leader peptide
(1-23 amino acids) (Kopan, Schroeter et al. 1996) in the presence or absence of
-secretase inhibitor L-685,458. As shown in Figure 1. 4a, recombinant NotchΔE
was detected with anti-myc antibody at various levels in wild-type and knockout
cells, possibly due to different transfection efficiency. As shown in the middle
panel, NICD, which is produced by -secretase from NotchΔE, was detected in
wild-type cells (lane 13), PS2-/- cells (lane 9), and PS1-/- cells (lane 7), Aph-1-/cells (lane 1), and NCT-/- cells (lane 3), and the formation of this NICD was
strongly inhibited by the addition of L-685,458 (lanes 2, 4, 8, 10, and 14).
However, this NICD was not detected in PS1/2-/- cells (lane 11) nor Pen-2-/- cells
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(lane 5). These results revealed an interesting finding that, under our
experimental conditions, NCT is crucially essential for -secretase-catalyzed APP
CTFs processing, but is not absolutely required for -secretase-catalyzed Notch
processing.
Generation of NICD from NotchΔE is not affected by proteasome and
lysosome inhibitors
Data presented in Figure 1. 2 demonstrate that CTFα was also degraded by
proteasome and lysosome in a -secretase-independent mechanism. Next, we
determined whether Notch is also subjected to proteasome and/or lysosome
degradation and whether proteasome and lysosome inhibitors have any effect on
NICD formation. As shown in the middle panel of Figure 1. 4b, -secretase
inhibitors compound E (lane 4) and, specifically, L-685,458 (lane 5) strongly
inhibited the formation of NICD from NotchΔE. However, the level of NICD in
proteasome inhibitors-treated cells was slightly increased (lanes 6 and 7), likely
due to the protection of NICD from degradation, while the lysosome inhibitors
showed no effect on the generation of NICD (lanes 8–10). In addition, the level of
unprocessed NotchΔE was also slightly increased in proteasome inhibitor-treated
cells (top panel, lane 6 and 7), suggesting that, though to lesser extent, NotchΔE
also underwent proteasome degradation. Taking together, these data suggest
that both NotchΔE and NICD undergo proteasome degradation, but the
proteasome and lysosome inhibitors have no effect on -secretase-catalyzed
processing of Notch.
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Recovery of PS1C does not necessarily restore the -secretase activity
toward APP in NCT-/- cells.
Previous study revealed that Pen-2, Aph-1, and NCT are not necessary for
endoproteolytic processing of PS1, but are required for stabilization of the PS1
endoproteolytic processing products PS1N and PS1C (Mao, Cui et al. 2012).
Thus, it is speculated that the loss of -secretase activity toward CTFα and CTFβ
might have resulted from the instability of endoproteolytic products of PS1 in
NCT-/- and Pen-2-/- cells. As shown in the top panel of Figure 1. 5, in the absence
of MG132, PS1C was detected in wt cells (lane 9), in PS2-/- cells (lane 5), and, to
a lesser but significant extent, in Aph-1-/- cells (lane 1). A very low level of PS1C
was detected in NCT-/- cells at (lane 3), and only a trace amount of PS1C was
detected in Pen-2 cells (lane 7). As expected, no PS1C was detected in PS1 -/cells (lane 11). This result confirmed again that Pen-2 is crucial for stabilizing
PS1C. This result also revealed that Aph-1 is less important for stabilizing the
endoproteolytic products of PS1.
When the cells were treated with MG132, a significant decrease in the level of
PS1C and a concomitant significant increase in the level of CaspPS1C produced
by caspase activity were detected in wt cells (lane 10), PS2-/- cells (lane 6), and
Aph-1-/- cells (lane 2). In the presence of MG132, CaspPS1C was also detected
in NCT-/- and Pen-2-/- cells (lanes 4 and 8). However, in contrast to wt, PS2-/-, and
Aph-1-/- cells, the increase in CaspPS1C was not associated with a decrease, but
rather an increase in the regular PS1C in NCT-/- cells (compare lane 4 with lane
37

3) and Pen-2-/- cells (compare lane 8 with lane 7). Interestingly, as shown in the
bottom panel, the high levels of unprocessed CTFα(endo), CTFα-myc, and CTFβ
in NCT-/- and Pen-2-/- cells were not affected by the addition of MG132. These
results indicate that recovery of PS1C does not necessarily restore -secretase
activity toward CTFα and CTFβ. In other words, Pen-2 and, specifically, NCT, as
essential components of -secretase, must play a direct role in -secretase
activity in addition to their roles in stabilizing PS1 proteolytic products. In this
regard, NCT has been proposed to function as a substrate receptor (Shah, Lee
et al. 2005).

Discussion
Previous studies using reconstitution and knockdown approaches have
suggested that the four proteins, presenilin (PS1 or PS2), NCT, Aph-1, and Pen2, are necessary and sufficient for -secretase activity (Edbauer, Winkler et al.
2003, Kimberly, LaVoie et al. 2003, Takasugi, Tomita et al. 2003). However, this
view was challenged by a recent study showing that Notch was processed in a secretase-dependent manner in NCT-deficient cells, suggesting that NCT is not
absolutely required for -secretase activity (Zhao, Liu et al. 2010). In the current
study, by taking advantage of the availability of all cell lines deficient in one of the
four components of the -secretase complex, we performed a series of
experiments to attempt to address this controversial issue. Using these cells, our
results demonstrated that knockout of PS2 had almost no effect on APP CTFs
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processing and that, in contrast, knockout of PS1 strongly inhibited APP CTF
processing as determined by the turnover of CTFα, as well as the formation of
AICD and Aβ40. These observations confirmed that PS1 accounts for the majority
of -secretase activity that catalyzes the processing of APP CTFs. In addition, our
results revealed several interesting findings. First, our data demonstrate that, in
contrast to NCT-/- and Pen-2-/- cells, in which no significant CTFα turnover and
only a small amount of Aβ40 was detected, similar to wt cells, a low level of CTFα
and significant amount of AICD were detected in Aph-1-/- cells. Also, the turnover
of CTFα and the formation of AICD were strongly inhibited by -secretase
inhibitor, suggesting that the turnover of CTFα and the formation of AICD in Aph1-/- cells, as well as in wt cells, were catalyzed by -secretase. In addition,
another -secretase substrate, Notch, was also processed in a -secretasedependent manner in Aph-1-/- cells. Furthermore, based on the levels of Aβ40
determined by ELISA, it is assumed that over 50% of -secretase activity was
retained in Aph-1-/- cells. Although it cannot be ruled out that the trace amount of
the residual Aph-1c, which was not detectable at the protein level under our
experimental conditions, may contribute to a small portion of the -secretase
activity in Aph-1-/- cells, all these observations strongly suggest that Aph-1 is not
absolutely required for -secretase activity. In addition, albeit at a very low level,
the detection of Aβ40 by ELISA in NCT-/- and Pen-2-/- cells suggests that deletion
of one of these two components does not completely abolish -secretase activity.
Thus, it is very likely that Aph-1, NCT, and Pen-2 are all required for achieving
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maximal -secretase activity; however, Aph-1 is less crucial than NCT and Pen-2
for the enzymatic activity in this -secretase complex.
It is proposed that -secretase harbors both endopeptidase-like and
carboxypeptidase-like activities, catalyzing a series of sequential cleavages of
APP and leading to the generation of Aβ peptide. In this model, APP is first
cleaved at the ε-cleavage site by endopeptidase-like activity to release the APP
intracellular c-terminal domain, AICD, and generate the membrane-bound, long
Aβ49 peptide, which is further sequentially chopped down roughly every three
residues by carboxypeptidase-like activity to produce the secreted Aβ40 and Aβ42
and other minor, shorter Aβ species (Xu 2009). Previous studies suggest that
Aph-1 might function as a scaffold involved in -secretase complex assembly and
maturation (LaVoie, Fraering et al. 2003, Luo, Wang et al. 2003) and in the
binding of substrate (Chen, Guo et al. 2010, Mao, Cui et al. 2012). In determining
the specific roles of different isoforms of Aph-1 in -secretase-catalyzed APP
processing, recent studies further suggest that Aph-1 mainly affects the
carboxypeptidase-like activity that catalyzes the sequential cleavages following
the initial cleavage at the ε-site and determines the C-termini of Aβ species;
specifically, -secretase complexes containing the Aph-1b isoform favor the
generation of longer Aβ peptides (Serneels, Dejaegere et al. 2005, Serneels, Van
Biervliet et al. 2009, Acx, Chávez-Gutiérrez et al. 2014). This notion might
provide justification for our finding that Aph-1 is dispensable for the
endopeptidase-like activity of -secretase that catalyzes the initial cleavage of
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CTFs at the ε-site, which is a decisive step in -secretase-catalyzed APP
processing (Xu 2009).
The second important finding of the current study is the differential
requirement for NCT in -secretase-catalyzed processing of APP and Notch. To
elucidate the specific function of NCT, a well-designed study revealed that the
extracellular domain of NCT is essential for recognition of the substrate of secretase, suggesting that NCT functions as a receptor of substrate (Shah, Lee
et al. 2005). However, a recent study showing that cells deficient in NCT were
capable of processing Notch and, to a lesser extent, APP in a -secretasedependent manner raised a question as to whether NCT is absolutely required
for -secretase activity (Zhao, Liu et al. 2010). Using the same NCT-/- cells and
the same truncated Notch-expressing plasmid as used in Zhao et al’s study, our
results revealed a similar finding that Notch was processed by -secretase
activity in the absence of NCT. In addition, our results revealed that Aph-1 was
also not absolutely required for Notch processing. However, in contrast to the
previous study, our data demonstrate that knockout of NCT completely abolished
-secretase-catalyzed processing of CTFα and CTFβ produced from both
endogenous and recombinant APP.
These controversial observations might have resulted from the use of
different experimental systems. Specifically, in the previous study, a transientlyexpressed truncated APP (C99), an artificial CTFβ, was used as a -secretase
substrate to determine the effect of knockout of NCT on the formation of AICD
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from C99. In contrast, in the current study, we examined the processing of CTFα
and CTFβ produced either from endogenous APP or recombinant full-length
APP. After synthesis, full-length APP undergoes multiple post-translational
modifications including N- and O-glycosylation, phosphorylation, and tyrosine
sulphation, and these modifications not only affect the trafficking but also the
processing of APP along the secretory pathway as well as the endocytotic
pathway (Jiang, Li et al. 2014). It is not known whether the overexpressed C99
also undergoes similar post-translational modification and is processed at the
same subcellular locations as full-length APP. Whether possible differences in
post-translational modification and trafficking may account for the discrepancy
between results of the current study and that reported by Zhao et al awaits
further investigation. Nevertheless, the data presented in this study strongly
suggest that NCT is crucially essential for -secretase-catalyzed processing of
CTFα and CTFβ produced from full-length APP, but that NCT is not absolutely
required for Notch processing. Supporting our finding, a recent study reported
that mutations in NCT differentially affect Aβ production and Notch processing
(Pamrén, Wanngren et al. 2011). Thus, this differential requirement for NCT in secretase-catalyzed processing of APP and Notch suggests NCT as a
therapeutic target for developing a strategy to restrict Aβ formation in AD without
impairing Notch signaling.
The third notable finding of the current study is that components of the secretase complex essential for -secretase-catalyzed APP processing are also
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important for proteasome- and lysosome-dependent degradation of APP
derivatives. Previous studies have reported that, in addition to -secretasecatalyzed processing, APP and CTFs of APP are also subjected to proteasome
and lysosome degradation (Skovronsky, Pijak et al. 2000, Nunan, Shearman et
al. 2001, Vingtdeux, Hamdane et al. 2007, Watanabe, Hikichi et al. 2012, Wang,
Sang et al. 2015). In the current study, as shown in Figure 1. 1 and 1. 2, our
data demonstrate that proteasome inhibitor MG132 and, specifically, lysosome
inhibitors chloroquine, leupeptin, and NH4Cl caused marked accumulation of
unprocessed APP CTFs in wild-type cells. A similar effect of these inhibitors on
the accumulation of APP CTFs was also observed in PS1 -/-, PS2-/-, and Aph-1-/cells, which all expressed the -secretase activity that catalyzes the processing of
APP CTFs. However, the effects of these inhibitors on the accumulation of the
APP CTFs was less significant in PS1/2-/-, NCT-/-, and Pen-2-/- cells, in which no
-secretase-catalyzed APP processing was observed. These findings strongly
indicate that presenilin (PS1 or PS2), NCT, and Pen-2, which are essential for secretase-catalyzed APP processing, are also important for proteasome- and
lysosome-dependent degradation of APP CTFs. One possibility is that secretase activity is involved in the proteasome- and lysosome-dependent
degradation of APP CTFs. However, this is very unlikely in light of the fact that secretase inhibitors and the proteasome and lysosome inhibitors exhibited
additive effects on the accumulation of APP CTFs. Recent studies reported that
presenilin is necessary for efficient protein degradation by lysosome in a 43

secretase-independent manner (Lee, Yu et al. 2010, Neely, Green et al. 2011,
Coen, Flannagan et al. 2012, Zhang, Garbett et al. 2012). In this regard, it is
noteworthy that our results suggest that lysosome plays a major role in
degradation of APP CTFs. Therefore, the inefficient degradation of APP CTFs in
PS1/2-/- cells is likely due to impaired lysosome function caused by deficiency of
presenilin. Since NCT and Pen-2 are essential for stabilizing presenilin (Mao, Cui
et al. 2012), the ineffective lysosomal degradation of APP CTFs in NCT -/- and
Pen-2-/- cells might have resulted from the instability of presenilin in these cells. It
is also noted that the level of PS1C in Aph-1-/- cells is much higher than that in
NCT-/- and Pen-2-/- cells, and this might account for the fact that lysosomal
degradation of APP CTFs was observed in Aph-1-/- cells. However, it cannot be
ruled out that NCT and Pen-2 may be directly involved in PS1-regulated
lysosome function rather than simply stabilizing PS1C. In addition, our results
strongly suggest that endogenous and exogenous APPs undergo degradation by
different mechanisms, i.e., endogenous APP mainly undergoes lysosomedependent degradation, whereas, exogenously expressed APP is primarily
degraded by proteasome.
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Figure 1. 1 Aph-1 is dispensable for γ-secretase catalyzed APP processing.
Cells were cultured in the presence and absence of γ-secretase inhibitor L685,458 (a) or MG132 (b) overnight, lysed, and subjected to 16% SDS-PAGE
and Western blot analysis using antibody C15 that was raised against the very cterminal 15 residues of APP. The membranes were also reprobed with antiGAPDH to indicate even loading of the samples (bottom panels). All data
presented in this study are representative of at least three independent
experiments. (c) Cell-free assay for in vitro generation of AICD. AICDendo: AICD
produced from endogenous APP; AICDmyc: AICD produced from myc-tagged
exogenous APPSw in a wt-7 stable cell line, which was used as a positive
control. (d) Effect of knockout of different components of γ-secretase on Aβ
formation. Aliquots of CM samples of knockout cells were subjected to ELISA to
detect Aβ40. A significant amount of Aβ40 was detected in Aph-1-/- cells, as well as
in wt cells. Low amount Aβ40 was also detected in PS1-/- cells, and even lower
Aβ40 was detected in NCT-/- and Pen-2-/- cells. N = 3, *p < 0.01; **p < 0.001. (e)
Western blot analysis of protein levels of γ-secretase components in knockout
cells. (f) RT-PCR analysis of NCT and Aph-1 genes in corresponding knockout
cells. Note: Since Aph-1c is the duplicate of Aph-1b in mice, the antibody against
Aph-1b also detects Aph-1c, and the RT-PCR primers used are also common to
both Aph-1b and Aph-1c.
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Figure 1.1 a

Figure 1.1 b

Figure. 1. 1 c

Figure 1. 1d
Figure 1.1 continued
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Figure 1. 1e

Figure 1. 1f

Figure 1.1 continued
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Figure 1.2 Components of the γ-secretase complex also play a role in regulating
APP degradation by proteasome and lysosome. (a) Effects of γ-secretase,
proteasome, and lysosome inhibitors on the accumulation of unprocessed
endogenous CTFα. The first lane is the vehicle-treated control. The last lane is
the sample prepared from wt-7 cells treated with γ-secretase inhibitor compound
E (compE) used as standards of CTFβ-myc and CTFα-myc. (b) In lanes 3–10,
cells were transfected with human APPsw expression plasmid. In lane 2, cells
were transfected with unrelated protein LacZ. In lane 1, cells were mock
transfected with an empty vector. Lane 11 is the sample prepared from wt-7 cells
treated with compound E used as standards of CTFβ-myc and CTFα-myc. All
APP CTFs were detected using C15. (c) Quantitative analysis of the formation
and turnover of APP-CTFs. Results are expressed as the mean (± SD) of three
independent Western blot results shown in Figure 1. 2b.
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Figure 1. 2a

Figure 1. 2b
Figure 1.2 continued
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Figure 1. 2 c
Figure 1.2 continued
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Figure 1.3 γ-secretase, proteasome, and lysosome inhibitors have an additive
effect on CTFα accumulation in Aph-1-/- cells. (a) Cells in lanes 2–10 were
cultured in the presence of γ-secretase inhibitors and proteasome and caspase
inhibitors either individually or in combination. Top panel, immunoblot probed
with C15; second panel, immunoblot probed with anti-caspase-3 to detect the
formation of the active form of caspase-3; third panel, immunoblot probed with
anti-caspase-6 to determine the reduction of pro-caspase-6 due to activation;
fourth panel, immunoblot probed with anti-PS1C, which reacts with both regular
PS1C and the caspase-produced CaspPS1C (#5643 from Cell Signaling); the
immunoblot in the fourth panel was also reprobed with anti-GAPDH to indicate
relative loading of samples (bottom panel). Lane 11 is the sample from wt-7 cells
cultured in the presence of compound E. (b) Cells in lanes 2–10 were cultured in
the presence of γ-secretase inhibitors and lysosome inhibitors either individually
or in combination. Top panel, immunoblot probed with C15; bottom panel, this
immunoblot was reprobed with anti-GAPDH. Lane 11 is the sample from wt-7
cells cultured in the presence of compound E.
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Figure 1. 3 a

Figure 1. 3 b
Figure 1.3 continued
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Figure 1. 4 a

Figure 1. 4 b
Figure 1.4 Aph-1 and nicastrin are not essential for γ-secretase catalyzed
processing of Notch. (a) Aph-1-/- cells were transfected with a plasmid expressing
N-terminal truncated Notch with a C-terminal myc tag. Top panel, immunoblot
probed with anti-myc to detect the unprocessed recombinant Notch. Middle
panel, immunoblot probed with antibody, which specifically recognizes the Nterminus of NICD generated by γ-secretase processing. Bottom panel,
immunoblot in the middle panel reprobed with anti-GAPDH. (b) Proteasome and
lysosome have no significant effect on Notch metabolism. Top panel, immunoblot
probed with anti-myc to determine the levels of NotchΔE in the presence of
different inhibitors; middle panel, immunoblot probed with anti-NICD; bottom
panel, immunoblot in middle panel was reprobed with anti-GAPDH.
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Figure 1. 5
Figure 1.5 Recovery of PS1C does not necessarily restore the γ-secretase
activity toward APP in NCT-/- cells. Knockout cells were cultured in the presence
or absence of MG132. Up panel, immunoblot probed with anti-PS1C that
recognizes both regular and caspase produced PS1C; bottom panel, immunoblot
probed with C15. Lane 12 is the sample prepared from wt-7 cells treated with
compound E used as standards of CTFβ-myc and CTFα-myc.
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CHAPTER II
THE ROLES OF GAMMA SECRETASE
COMPONENTS IN APOPTOSIS AND THE
FUNCITONS OF VARIED LENGTH OF PS1C
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Abstract
In the previous chapter, we investigated the γ-secretase activity in various knock
out cells. In this chapter, we found that the apoptosis in these knockout cells
varied too. Aph-1-/- cells show a higher susceptibility to apoptosis, induced by
MG132 via downregulation of Akt-mediated anti-apoptotic pathway. We also
found several forms of PS1C, but the function of them remain unclear. In this
chapter, we also used different methods to investigate the function of these forms
in -secretase activity. The results of transfecting varied forms of PS1C back to
PS1/2-/- double knockout cells shown that all the PS1C forms could process
Notch when transfecting together with PS1N. However, only the shorter form of
PS1C299 shown significant effects on restoring secretase activity toward APP
processing. The phosphorylation of PS1C does not show significant effect on
secretase catalyzed CTF processing under our experimental conditions.

Introduction
MG132, which is known as a proteasome inhibitor, could also induce apoptosis
and autophagy at higher concentration through the upregulation of ER stress in
various cells (Park, Jun do et al. 2011, Bao, Gu et al. 2016). Treatments of MAP
kinase (JNK, p-38, MEK and so on) inhibitors were reported to be able to reduce
apoptosis induced by MG132 (You and Park 2011), suggesting that these
kinases contribute to MG132-induced apoptosis. Numbers of transcriptional
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factors like NF-B, p53 and stat3 were reported to be involved in the autophagy
induced by proteasome inhibitors (Saji, Higashi et al. 2011, Pietrocola, Izzo et al.
2013). The addition of MG132 could induce the activation of a series of apoptosis
related protein: like caspase 3, 7, 9, Bak, PARP and so on (Park, Jun do et al.
2011). Unlike kinases mentioned above, which promote apoptosis upon
activation, the activation of Akt was shown to suppress apoptosis (Qin, Wang et
al. 2010, Kahana, Finniss et al. 2011). Like ERK and PKC, Akt is regarded as a
suppressive kinase in cell death induction (Scanga, Ruel et al. 2000, Franke,
Hornik et al. 2003). Activated Akt (p-Akt) can phosphorylate and inactivate GSK3
(Ruvolo, Qiu et al. 2015). Therefore, the level of phosphorylated GSK3 could be
used as an indicator for the activation of Akt.
In this study, we found that the same concentration of MG132 could induce
varied level of apoptosis in different knock out cells. Among these cells, Aph-1-/cells have a higher tendency of apoptosis based on the levels of PARP cleavage
and activation of caspase 3 and caspase 7. The phosphorylation levels of
kinases which mediate apoptosis, like JNK, p-38, c-Jun (Ferraris, Isoniemi et al.
2012) and transcriptional factor CHOP (Teske, Fusakio et al. 2013) were found
increased in Aph-1-/- , NCT-/-, Pen-2-/-, PS1-/-, PS2-/- and WT cells. But unlike the
other knock out cells, the level of the active form of the apoptosis suppressive
kinase p-Akt is reduced in Aph-1-/- cells. The downregulation of p-Akt in the
absence of Aph-1 might account for the higher tendency of apoptosis in Aph-1-/cells. Based on the previous results, p-GSK3 located downstream of p-Akt is
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phosphorylated by p-Akt. Therefore, the reduction of p-GSK3 is consistent with
the reduction of p-Akt and further confirmed that the downregulation of p-Akt in
the absence of Aph-1 upon treatment with MG132.
PS1 was first reported of going through endoproteolysis at 1996 and the
cleavage sites range from 260aa to 320aa (Thinakaran 1996). Later report
identified the more specific processing sites located on aa292. Since the
mutation at aa 292 could almost abolish the endoproteolysis of PS1 (Steiner,
Romig et al. 1999). Further investigation revealed that like -secretase substrate
APP, the endoproteolyis of PS1 also follows a three-amino acid spacing manner
and occurs sequentially at multiple sites at aa 293, aa 296 and aa 299 (Xu 2009,
Fukumori, Fluhrer et al. 2010).
An apoptotic fragment of PS1 and PS2 were first reported of cleavage results
by caspase 3. And the cleavage sites in PS1 was reported within 343aa to 346aa
(Kim 1997). Two years later, besides the above one, another cleavage site was
detected at 329 aa which is processed by the group of caspase 8, 6 and 11
(Craen 1999). In addition to the normal PS1C and caspase cleaved PS1Cs,
phosphorylated PS1Cs were also reported. For example, the one phosphorylated
by GSK3 at Ser353, Ser357 or Ser397, Ser401 (Kirschenbaum, Hsu et al. 2001,
Twomey and McCarthy 2006), the one phosphorylated by cyclin-dependent
kinase 5/p35 (cdk5/p35) on Thr354(Lau, Howlett et al. 2002), a PKC
phosphorylated one on Ser346(Fluhrer, Friedlein et al. 2004) and so on. A recent
paper have check almost all the phosphorylated PS1 and conclude that these
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phosphorylation of PS1 do not modulate the activity of -secretase and therefore
should not be considered as targets of AD treatment (Matz, Halamoda-Kenzaoui
et al. 2015).
Based on our previous results and the papers mentioned about all the PS1
fragments above, including PS1N (1-292aa), PS1C (PS1C293, PS1C296, PS1C299,
PS1C334, PS1C346 and phosphorylated PS1), we suspect that they might have
different effects on γ-secretase activities. Therefore, we designed several
experiments to determine their function. First, we used phosphatase to remove
the phosphorylation of PS1C and check the activity of PS1C at process CTFs
and found that the phosphorylation of PS1C does not contribute to gamma
secretase activity. Then we also constructed different forms of PS1Cs, the
PS1C293, PS1C296, PS1C299, PS1C334 and PS1C346 and a PS1N (1-292aa). We
transfected these PS1Cs in combination with PS1N back to PS1/2-/- cell together
with NotchΔE or APPsw. We found that the transfection with PS1C (no matter
which form) alone or PS1N alone could not process NotchΔE or APP. While,
when both PS1N and PS1C (no matter which PS1C form) were transfected into
cells together, processing of NotchΔE was readily detectable. However, the
ability of these PS1Cs to process APP was different. Our results demonstrated
that the PS1C299 is the most effective form in processing APP in comparison with
other PS1C of different length. This result suggests that PS1C299 might contribute
more to APP processing.
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Materials and Methods
Cell culture
MEF cells we used in this part were the same from the last chapter: including
Aph-1-/- , NCT-/-, Pen-2-/-, PS1-/-, PS2-/-, PS1/2-/-, wild type (wt) and wt-7 cells. All
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Lonza,
Walkersville, MA, USA) which containing 10% fetal bovine serum, 2 mM Lglutamine (Lonza), 100 units/mL penicillin (Lonza), and 100 μg/mL streptomycin
(Lonza).
Inhibitors and reagents
We used proteasome inhibitor MG132 and gamma-secretase inhibitor
Compound E in this chapter and like which mentioned in last chapter: MG132
was purchased from Peptides International (Louisville, KY, USA), Compound E
and DAPM were purchased from EMD Millipore (Billerica, MA, USA). Complete
protease inhibitor cocktail tablets were purchased from Roche Applied Science
(Indianapolis, IN, USA). Lipofectamine LTX and plus reagent was purchased
from Invitrogen (Carlsbad, CA, USA). Phosphatase was purchased form SigmaAldrich (St. Louis, MO, USA).
Antibodies
Antibodies which were anti-PS1C5643, PS1C3622, c-Notch (#4147, which
specifically recognizes the processed Notch), PARP, caspase3, caspase-7, pcJun, p-JNK, JNK, p-p38, p38, CHOP(C/EBP-homologous protein), p-Akt, Akt,
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and p-GSK3 (Ser-9) were purchased from Cell Signaling (Danvers, MA).
Polycolonal antibody C15 was raised against the last 15 amino acids at the very
C terminal of APP (Zhao, Mao et al. 2004). Polycolonal antibody 6E10 was
purchased from Covance (Princeton, NJ, USA). Anti-myc antibody, C-Myc
(9E10), was purchased from Santa Cruz (Dallas, TX, USA). Anti-GAPDH
(glyceraldehyde 3-phosphate dehydrogenase) was from EMD Millipore (Billerica,
MA).
Plasmids
We used NotchΔE and APPsw plasmid which as mentioned in last chapter:
plasmid expressing the extracellular region truncated and myc-tagged Notch
molecule (NotchΔE) containing the murine Notch-1 leader peptide (1-23 aa)
(Kopan, Schroeter et al. 1996) was kindly provided by Raphael Kopan
(Washington University) and Dr. Masayasu Okochi (Osaka University, Japan).
The plasmid APPsw, which expresses a C-terminal myc-tagged Swedish mutant
APP (APPsw) (Thinakaran, Teplow et al. 1996), was kindly provided by Dr Gopal
Thinakaran (University of Chicago). The plasmids which expressing the PS1N
terminal (1-292aa), PS1C terminals: PS1C293 (293-467aa), PS1C296 (296-467aa),
PS1C299 (299-467aa), PS1C334(334-467aa), PS1C346 (346-467aa) were
constructed in our lab and sequenced to confirm.

67

SDS-PAGE and Western blotting
For analysis of apoptosis and autophagy related proteins, 10 h after splitting,
cells were incubated overnight in the presence or absence of MG132 at different
concentrations (check the legends for concentration details). For the analysis of
the activity of gamma secretase, gamma secretase inhibitor compound E (5nM)
was applied the same like above. For analysis of the exogenous APP and Notch
processing through different PS1C and PS1N terminals, the cells, 24 h after
splitting, were transfected with plasmids expressing APPsw or NotchΔE with
lipofectamine LTX. Twelve hours after the transfection of APPsw or NotchΔE,
PS1N and PS1C terminals were transfected and the cells were further incubated
for about 24 hours. For the detection of the function of phosphorylated PS1C,
cells were grown for 24 hours and then collected with dephosphorylation buffer
(suggested by sigma) and incubated in 37℃ for 2 hours with inhibitors and
phosphatase (check figures and figure legend for details). Cell lysis and Western
blot analysis were carried out as described previously (Zhao, Mao et al. 2004),
which is consistent to which described briefly in last chapter. The membranes
were probed with appropriate antibodies as described in Figure legends.

Results
Presenilin 1 C terminal levels varied in different knock out cells with the
addition of MG132.
As a proteasome inhibitor, MG132 could block the degradation of PS1 C
terminals from degrading through proteasome pathway. Therefore, the
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accumulation of PS1 C supposed to be observed with the presence of MG132 in
the knock out cells. Increased levels of PS1 C were observed in NCT knock out
(Figure 2.1 upper panel, compare lane 4 with lane 3) and Pen-2 knock out cells
(lane6 with lane5), even the volume differed. In PS2 knock out cells and WT cells,
the level of regular PS1C seemed unchanged with the detection of one antibody
(5643 from cell signaling, upper panel, compare lane 10 with lane 9, lane 12 with
lane 11). But the levels of PS1 C were increased with the detection of another
antibody (3622 from cell signaling, the lower panel), which is due to the fact that
different epitopes were recognized by these two antibodies. Antibody 3622 could
recognize the PS1 C from aa293 to aa313, based on our experiment, it could
only recognize the longer form of PS1 C, which is from the amino acid 293 (aa)
to aa467 (PS1C293 in short), but could not recognize the other forms, like the
peptide start from aa 296 to aa467 (PS1C296 in short), aa299 to aa467 (299 in
short) or the even shorter forms which are processed by caspases (picture2.1,
upper panel). Based on the results detected by antibody 3622, the level of longer
form: PS1C293 was marginally expressed in different knock out cells and WT cell
(lane1, 3, 5, 9 and 11, figure2.1 lower panel). The majority of PS1C was either
processed into short form: PS1C296 and PS1C299 or go through random
degradation through proteasome pathway. As shown in figure 2.1, with the
addition of proteasome inhibitor MG132, PS1 C’s level was dramatically
increased when detected with 3622 in all knock out cells besides Aph-1 knock
out cells and WT cells. When combined with the results detected by 5643
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antibody which could detect all the PS1 C terminals, including the PS1C293,
PS1C296, PS1C299 and the caspase cleaved PS1Cs, we can see the level of total
PS1 C was much lower in Aph-1 knock out cells, especially when comparing with
NCT knock out cells (compare lane 2 with lane 4, figure2.1 upper panel). On the
other hand, the caspase cleaved PS1 C was much higher in Aph-1 knock cells
(compare lane 2 with lane 4, picture2.1 upper panel). Therefore, we speculate
that the majority of PS1C were processed through caspase activity in Aph-1
knock out cells. Cells have higher apoptosis rate when induced by MG132 in
Aph-1 knock out cells.
Subsequently, we conducted the following experiments to check the caspase
activity in all knock out cells and WT cells with the presence of MG132.
Cells have a higher tendency of apoptosis with MG132 addition in the
absence of Aph-1.
Based on the results in Figure 2.2, comparing lane 2 with lane 4, 6, 8, 10 and 12,
the level of active form of caspase 3, caspase 7 and the cleavage of PARP were
much higher in Aph-1 knock out cells than which induced in NCT knock out cells,
Pen-2 knock out cells, PS1 knock out cells, PS2 knock out cells and WT cells by
MG132. Therefore, we can conclude that the some concentration of MG132
addition trigger more apoptosis in the absence of Aph-1. We also noticed that
knock out of NCT and PS2 could also result in a higher tendency of apoptosis but
was much less compared to which caused by the deletion of Aph-1.
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Apoptosis suppressive protein is down regulated in Aph-1 knock out cells.
Since MG132 is a proteasome inhibitor and an autophagy inducer and thus could
induce apoptosis through the upregulation of ER stress with the accumulation of
redundant proteins. Since the previous experiment has already demonstrated
that caspase activity is much stronger in the absence of Aph-1, we examined the
kinases involved in apoptosis. Based on the results in Figure 2.3, pro-apoptotic
kinases p-c Jun, p-JNK, p-p38 were upregulated in a similar level in all the cells.
However, the level of p-Akt (anti-apoptotic kinase) was highly differed in different
cells with the addition of MG132. Compare lane 3 with lane 4, lane 5 with lane 6,
MG132 induced higher expression of p-Akt in NCT knock out cells and Pen-2
knock out cells which could result in reduction of apoptosis. For PS1 knock out
cells and WT cells, the level of p-Akt remained similar even with the addition of
MG132. However, in PS2 knock out cells the p-Akt level was a litter bit lower.
The dramatic reduction of p-Akt was found in Aph-1 knock out cell. The
significant reduction of apoptosis suppressive protein: p-Akt, in Aph-1 knock out
cells could be a reasonable cause that could explain the higher induction of
apoptosis in Aph-1 knock out cells. The p-GSK3 which is phosphorylated through
p-Akt followed the same pattern of p-Akt (Figure 2.3 the panel detected with pGSK3). The reduction of p-GSK3 level was much obvious in Aph-1 knock out
cells than the other cells (compare lane 2 with lane1, lane 4 with lane 3, lane 6
with lane 5, lane 8 with lane7, lane 10 with lane 9 and lane 12 with lane11).
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The difference of apoptosis induced with MG132 become significant at the
concentration of 5uM.
The concentration of MG132 we used in previous experiments is 5uM since it is a
recommended concentration as a proteasome inhibitor. But how it affects
apoptosis and the activation of Akt are not known, so different concentration of
MG132 were tested in Aph-1 knock out cell, NCT knock out cell and WT cell. The
reason we choose Aph-1 knock out cell and NCT knock out cell is that the
difference of PS1C detected in these two cells were most dramatic, which
indicate that the apoptosis in these two cells differ most from each other. Based
on the results of Figure 2.4, we found that the induction of caspase activity and
apoptosis induced kinase like p-c Jun, p-p 38, p-JNK follow a dose dependent
manner. We also found the increase of caspase activity in Aph-1 knock out cells
was faster which further support the idea that the absence of Aph-1 lead to
higher preference of apoptosis. The reduction of p-Akt and p-GSK 3 also
followed a dose dependent manner in Aph-1 knock cells and became very
significant at the concentration of 5uM which was used in the previous
experiments. We have also checked the effect of the addition of higher
concentration of MG132. The results demonstrated that 5uM is suitable to show
the difference since the increased level of MG132 (10uM) did not cause more
reduction of p-Akt and p-GSK3 in Aph-1 knock out cells (Figure 2.5, compare
lane 4 with lane 3). Therefore, in this project, 5uM is a suitable concentration for
both proteasome degradation protection and apoptosis induction.
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The only transfection of PS1C terminal fragments or PS1N fragments could
not process NotchΔE.
To illustrate the potential functions of truncated PS1C terminals and N terminals
at restoring gamma secretase activity, we constructed varied PS1 C terminals
with the length from amino acid 293, 296, 299, 334, 346 to the very end of C
terminal (name as PS1C293, PS1C296, PS1C299, PS1C334 and PS1C346) and PS1
N terminal starting from amino acid 1 to 292 (short as PS1N). As shown in the
upper panel of Figure 2.6, with the detection of antibody 5643, PS1wt, PS1C293,
PS1C296, PS1C299, PS1C334 and PS1C346 and PS1N were successfully
transfected into the PS1/2 double knock out cells. The results shown by antibody
3622 confirmed that the band detected with 3622 was the longer form of PS1C
which was PS1C293 (lane 5), since the other forms of PS1 C could not be
detected by antibody 3622 (compare lane 5 with lane 6, 7, 8 and 9). The third
panel was probed with -myc antibody which shown similar transfection level of
NotchΔE in the cells transfected with varied PS1C terminals PS1N terminal.
Even with the equal transfection of NotchΔE, the processing of it differed
dramatically due to the transfection of varied PS1C and PS1N. In the panel
detected with c-Notch which could only recognize the processed C terminal of
NotchΔE, we found NotchΔE was only processed with the transfection of PS1wt
rather than any other PS1 C terminals or PS1 N terminal (compare lane 4 with
lane 5, 6, 7, 8, 9 and 10). This result demonstrated that the only transfection of
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PS1C or PS1N could not restore the activity of gamma secretase at processing
NotchΔE.
NotchΔE could be processed by the double transfection of PS1C terminal
fragments (all the truncated PS1 Cs) and PS1N fragments.
Since the single transfection of PS1C or PS1N could not process NotchΔE, we
suspect the processing of NotchΔE might require the integrity of PS1. So we
transfect different PS1C terminals separately but together with PS1N terminals,
results (Figure 2.7) shown that the transfection of PS1 Cs and PS1N were
successful (upper two panels). The NotchΔE expression in all the transfected
cells were equal (the third panel detected with -myc antibody). The results
shown by c-Notch immunoblot was interesting, all the PS1C transfected with
PS1N terminals could process NotchΔE and the c-Notch levels were similar to
which processed by PS1 wt plasmid (compare lane 5, 6, 7, 8 and 9 with lane 4 in
panel 4). This result demonstrated that the PS1Cs transfection together with
PS1N could restore the activity of -secretase at processing NotchΔE, and the
restoration is not obviously affected by the length of PS1 C. No matter how the
PS1C starts from 293, 296, 299, 334 or 346, they all could process NotchΔE with
PS1N.
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APP produced CTF could be processed by the double transfection of
PS1C terminal fragments (all the truncated PS1 Cs) and PS1N fragments
differently.
Another important substrate of gamma secretase is CTFs. Our results above
have already demonstrated the processing of NotchΔE does not differ with the
transfection of varied length of PS1 C. The next thing is to determine the pattern
of the processing of CTFs by varied PS1C terminals. Since our CTFs and PS1
levels in all the knock out cells suggest that the length of PS1 C might contribute
to the ability of gamma secretase at the processing of CTFs. The upper two
panels in Figure 2.8 demonstrated the success of the transfection of PS1 C and
PS1 N terminals in PS1/2 double knock cells. The third panels shown the
transfection of APP in all the lanes were similar. But immunoblot with C15
indicated that the levels of CTFs are different. There were three bands; the upper
one was exogenous CTFbut the level was so low to show clear difference; the
middle one was exogenous CTF. Without the transfection of APP, these two
exogenous bands could not be detected, as shown in lane 1, the only detected
band is endogenous CTFWe found that the transfection of PS1wt significantly
reduced the level of CTFs (all the three bands were reduced, compare lane 4
with lane 2 and 3). The interesting thing was the transfection of PS1C299 together
with PS1N seemed processed more CTFs than the other PS1C fragments. It is
suggesting that the short form of PS1 C (PS1C299) has higher activity at
processing CTFs.
75

Phosphorylated PS1C could not process CTF.
In the first panel of figure 2.9, the upper band is a phosphorylated PS1C, which
could be dephosphorylated by phosphatase (compare lane 2 with the other
lanes). First, in the absence of DAPM, even though PS1C was dephosphorylated
(compare lane 1 with lane 2 in the first panel), CTFwas not protected or
processed more (shown in the second panel) which suggest that the
phosphorylated PS1C was not active at processing CTF. However, another
possibility was that in the condition of dephophorylated buffer -secretase was
not active at all. Therefore, as a -secretase inhibitor, DAPM (3,5DIFLUOROPHENYLACETYL-ALA-PHG-OME) was added to test its activity.
Since DAPM might be removed during sample collection by multiple wash, it was
added during wash period too. Compare lane 3 and lane 2 in the second panel,
the processing of CTF was blocked, which confirmed that during the 2 hours
incubation period of samples in dephosphorylation buffer with phosphatase at
37℃, the activity of -secretase was not disturbed. Putting all together, the
dephosphorylation of PS1C did not block or promote the processing of
CTFthrough -secretase.

Discussion
Neuron loss is a major problem in AD. Therefore, apoptosis become a big issue
in the searching AD treatment and therapy. It has been reported that mutant PS1
and overexpression of PS1 could induce apoptosis (Weihl, Ghadge et al. 1999,
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Zeng, Hu et al. 2015). And one report mentioned that the overexpression of Aph1a, b and pen-2 could induce an anti-apoptotic result through downregulating p53 controlled activity of caspase 3 and the knock out of these components will
result in the reverse response which is increase of caspase activity and
apoptosis with the induction of staurosporine (STS). They conclude that the antiapoptotic response is independent of -secretase activity but require the integrity
of it (Dunys, Kawarai et al. 2007). Their theory and results are very supportive to
our research here. The difference is that the apoptotic inducer we used is
proteasome inhibitor MG132. We have found in previous study that the knock out
of different components of -secretase result in varied viability of induction by
MG132 (Hu, Zeng et al. 2015). But the exact roles of the -secretase component
in apoptosis induced by MG132 and the pathways involved in MEF cells remain
unclear. Therefore, we designed this study and found that in consistent to Dr.
Dunys’s study, indicating the knock out of Aph-1 lowering the resistance of MEF
cells to apoptosis. But the knock out of Pen-2 does not increase the level of
apoptotic related activities, such as the active form of caspase 3, 7, PARP and so
on, which is probably because we use different inducers and the pathways
involved are totally different.
For instance, in our case, the activation of p53 is not affected by MG132 (not
shown). However, the level of apoptosis suppression kinase p-Akt is dramatically
reduced in the Aph-1 knock out cells. And the kinase GSK3 which is
phosphorylated by p-Akt decreased correspondently, further supporting the idea
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that the increased apoptosis with the absence of Aph-1 is due to the lowering to
p-Akt with the induction of MG132 in MEF cells(Scanga, Ruel et al. 2000, Franke,
Hornik et al. 2003, Ruvolo, Qiu et al. 2015).
It still remains unknown how Aph-1 regulate p-Akt. The proper hypothesis
could be p-Akt is a substrate of Aph-1 or the kinase that phosphorylated p-Akt is
regulated by Aph-1 somehow. These directions need to be further pursued. Hope
we will come to a more specific conclusion in the future.
The other part of this study is to compare the activity of PS1C fragments in secretase through the processing of Notch and CTFs. The PS1N and PS1C
fragments containing plasmids were constructed based on previous reports(Kim
1997, Craen 1999) (Steiner, Romig et al. 1999) (Fukumori, Fluhrer et al. 2010).
The phorsphorylated PS1 were reported of no -secretase activity which is
consistent with our results (Matz, Halamoda-Kenzaoui et al. 2015). The
dephosphorylation of PS1C does not reduce the activity of -secretase.
For the processing of Notch by other PS1C fragments, we found that both
PS1N and PS1C are required. It is probably due to the necessary of the intact of
two aspartic site: D257 and D385 which are located on PS1N and PS1C
separately (Capell, Steiner et al. 2000). Since the PS1C fragments we created in
this study all include aa385 and PS1N include aa257. This hypothesis is
supported by a previous report (Kim, Ki et al. 2005) and require further
investigation.
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However, the activity of PS1C (PS1C293, PS1C296, PS1C299, PS1C334, PS1C346)
fragment at processing Notch with the accompany of PS1N do not varied
dramatically, Only PS1C293 shown less activity when comparing to the others.
However, at processing CTFs, the activity of PS1Cs varied obviously. The
PS1C299 has stronger strength than the others. Since it has been reported that
the endoproteolysis and production of PS1C is also stepwise and the final
produced PS1C is PS1C299 in cells, we may conclude that the shedding of the
first several amino acid is required for the processing of CTFs (Fukumori, Fluhrer
et al. 2010). Apparently, in our study, the caspase produced PS1C fragments
PS1C334 and PS1C346 do not have activity at processing CTFs. Based on above
results, the processing of Notch and CTFs require different length of PS1C. The
processing of CTFs is more complicated and need further investigation.
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Figure 2.1
Figure 2.1 Presenilin 1 C terminal levels varied in different knock out cells with
the addition of MG132. Knockout cells were cultured in the presence or absence
of MG132. Up panel, immunoblot probed with anti PS1C 5643 antibody that
recognizes both regular and caspase produced PS1C; bottom panel, immunoblot
probed with with anti PS1C 3622 that recognizes only longer form of PS1C starts
from amino acid 293.
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Figure 2.2
Figure 2.2 Cells have a higher tendency of apoptosis with MG132 addition in the
absence of Aph1.Knockout cells were cultured in the presence or absence of
MG132. Up panel, immunoblot probed with anti PARP; middle panel,
immunoblot probed with caspase 3 which could recognize the full length and
active form of caspase 3; bottom panel, immunoblot probed with caspase 7
which could recognize the full length and active form of caspase 7.
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Figure 2.3
Figure 2.3 Apoptosis suppressive protein is down regulated in Aph1 knock out
cells.Knockout cells were cultured in the presence or absence of MG132. And
immunoblot probed with anti p-c Jun, p-JNK, JNK, p-p38, p38, CHOP, p-Akt, Akt,
p-GSK3 separately. Then re-probe the p-p38 probed membrane with GAPDH for
loading control.
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Figure 2.4
Figure 2.4 The difference of apoptosis induced with MG132 become significant
at the concentration of 5uM. Knockout cells were cultured in the presence or
absence of MG132. And immunoblot probed with anti PARP, caspase 3, caspase
7, PS1 C 5643, PS1C 3622, p-c Jun, p-p38, p38, p-JNK, JNK, CHOP, p-Akt, Akt,
p-GSK3 separately. Then re-probe the p-p38 probed membrane with GAPDH for
loading control.
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Figure 2.5
Figure 2.5 The difference of apoptosis induced with MG132 become significant
at the concentration of 5uM. Knockout cells were cultured in the presence or
absence of MG132. And immunoblot probed with anti PARP, CHOP, p-Akt, Akt,
p-GSK3 separately. Then re-probe the CHOP probed membrane with GAPDH for
loading control.
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Figure 2.6
Figure 2.6 The only transfection of PS1C terminal fragments or PS1N fragments
could not process NotchΔE. PS1/2 double knockout cells were transfected with
different PS1 C terminals or PS1N terminals together with NotchΔE. And
immunoblot probed with anti PS1C5643, PS1C3622, -myc, c-Notch and
GAPDH separately.
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Figure 2.7
Figure 2.7 NotchΔE could be processed by the double transfection of PS1C
terminal fragments (all the truncated PS1 Cs) and PS1N fragments. PS1/2
double knockout cells were transfected with different PS1 C terminals and PS1N
terminals together with NotchΔE. And immunoblot probed with anti PS1C5643,
PS1C3622, -myc, c-Notch and GAPDH separately.
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Figure 2.8
Figure 2.8 APP produced CTF could be processed by the double transfection
of PS1C terminal fragments (all the truncated PS1 Cs) and PS1N fragments
differently. PS1/2 double knockout cells were transfected with different PS1 C
terminals and PS1N terminals together with APP. And immunoblot probed with
anti PS1C5643, PS1C3622, 6E10, C15 and GAPDH separately.
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Figure 2.9
Figure 2.9 Phosphorylated PS1C could not process CTF. WT cells were
treated in the presence or absence of DAPM (100nM). Phosphatase was added
in lane 2. And immunoblot probed with anti PS1C5643, C15 and GAPDH
separately
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CHAPTER III
PEN-2 IS REQUIRED FOR NOTCH PROCESSING
AS A SUBSTRATE RECEPTOR
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Abstract
Pen-2 is necessary for PS1 endoproteolysis and the stability of the heterodimer
of PS1N and PS1C. Therefore, we suspect that the inability of processing Notch
in Pen-2-/- cell is due to the instability of PS1. In order to test this possibility,
PS1N and PS1C299 alone with Notch were transfected into Pen-2-/- cell. However,
despite the presence of significant amount of PS1N and PS1C, no  secretase
activity was detected in these Pen-2-/- cells. This result suggests that Pen-2 is
functionally required for -secretase activity. Furthermore, Pen-2 and PS are the
two minimal components required for Notch processing since the knockdown of
NCT in Aph-1 knock out cell did not affect the processing of Notch. Furthermore,
with immunoprecipitation experiments, our results demonstrate that Pen-2 might
functionally required for recruit substrate Notch and assist in delivering Notch to
PS for processing. As shown in chapter II, our data have demonstrated that all
the PS1Cs (PS1C293, PS1C296, PS1C299, PS1C334 and PS1C346) examined
showed no difference in catalyzing Notch processing. But PS1C299 has a higher
activity for CTFs processing. Thus, PS1C299 was chosen as a PS1C
representative to carry out the following study. Our study supports the hypothesis
that Pen-2 is more than a structural component of the -secretase complex and
may contribute to the catalytic mechanism of the enzyme (Bammens, ChávezGutiérrez et al. 2011).
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Introduction
Presenilin enhancer 2 (Pen-2) is a 12kD, hairpin like membrane protein (De
Strooper 2003). Pen-2 was found to interact closely with PS and to be required
for -secretase activity for processing CTFand Notch (Francis, McGrath et al.
2002). Knockdown of Pen-2 resulted in the accumulation of holoprotein PS1 and
reduction of the endproteolytic product of PS1, PS1N and PS1C. Therefore, Pen2 was thought to be necessary for the endoproteolysis of PS (Takasugi, Tomita
et al. 2003). The endoproteolysis of PS is required for the activation of PS1
functioning as the catalytic component of -secretase (Kopan and Goate 2000).
Pen-2 was also reported to play a role in stabilization of PS1N and PS1C
heterodimer following endoproteolysis of PS1 (Prokop, Shirotani et al. 2004).
Using siRNA approach, it was shown that knockdown of pen-2 also resulted in
impaired NCT maturation and proteasomal degradation of other -secretase
components, suggesting that pen-2 is also important for maintaining the integrity
of -secretase complex (steiner, winkler et al. 2002, mao, cui et al. 2012). The
important role of Pen-2 in -secretase activity was further confirmed by a recent
study that reported that genetic knockout of Pen-2 resulted in embryo lethality
and embryo absorbing at embryonic day 9.5, likely due to impaired Notch
signaling (Bammens, Chavez-Gutierrez et al. 2011).
In 2012, our group found that Pen-2 might be dispensable for endoproteolysis
of PS1 (Mao, Cui et al. 2012). It was found that significant level of PS1C could be
recovered by addition of proteasome inhibitor MG132 in Pen-2 knockdown cells,
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strongly indicating that PS1 was processed in the absence of Pen-2. This result
suggests that Pen-2 is not absolutely required for PS1 endoproteolytic
processing, but rather more important for the stabilization of PS1 by preventing it
from proteasome degradation (Mao, Cui et al. 2012). This finding was further
supported by a very recent study reporting that PS1 is processed in Pen-2
knockout cells isolated form Pen-2 knockout mice (Holmes, Paturi et al. 2014)
These observations raised questions about whether Pen-2 participate in
secretase activity through the regulation the formation of PS1N and PS1C
heterodimer or Pen-2 is directly involved in -secretase catalytic mechanism per
se remain illusive. To elucidate the exact role of Pen-2 in secretase activity, we
conducted several experiments in this chapter. Our data clearly demonstrate that
Pen-2 is not required for the PS1N and PS1C heterodimer formation, bur is very
likely required for substrate recruitment of -secretase.

Materials and Methods
Cell culture
MEF cells we used in this part were: Aph-1-/- , Pen-2-/-, PS1/2-/-, wild type (wt) and
wt-7 cells. All cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Lonza, Walkersville, MA, USA) which containing 10% fetal bovine
serum, 2 mM L-glutamine (Lonza, Walkersville, MD), 100 units/mL penicillin
(Lonza), and 100 μg/mL streptomycin (Lonza).
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Inhibitors and reagents
Compound E, a secretase inhibitor was purchased from EMD Millipore
(Billerica, MA, USA). Complete protease inhibitor cocktail tablets were purchased
from Roche Applied Science (Indianapolis, IN). Lipofectamine LTX and plus
reagent was purchased from Invitrogen (Carlsbad, CA).
Antibodies
Antibodies which were anti-PS1C5643 and c-Notch (#4147, which specifically
recognizes the processed Notch) were purchased from Cell Signaling (Danvers,
MA). Polycolonal NCT antibody N1660 was purchased from Sigma-Aldrich
(St.Louis, MO). Polyclonal antibody anti-PEN-2N was from Covance (Emeryville,
CA). Anti-myc antibody, C-Myc (9E10), was purchased from Santa Cruz (Dallas,
TX, USA). Anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was from
EMD Millipore (Billerica, MA). Anti-PS1N was raised against a peptide
corresponding to residues 27–50 of human PS1 (Zhao, Cui et al. 2005).
Plasmids
We used NotchΔE plasmid which as mentioned in last chapter: plasmid
expressing the extracellular region truncated and myc-tagged Notch molecule
(NotchΔE) containing the murine Notch-1 leader peptide (1-23 aa) (Kopan,
Schroeter et al. 1996) was kindly provided by Dr. Raphael Kopan (Washington
University) and Dr. Masayasu Okochi (Osaka University, Japan). The plasmids
which expressing the PS1N terminal (1-292aa), PS1C terminals: PS1C293 (29397

467aa), PS1C296 (296-467aa), PS1C299 (299-467aa), PS1C334 (334-467aa),
PS1C346 (346-467aa) were constructed in our lab and sequenced. PS1 mutants
applied: PS1D257A, PS1D385A, PS1D257,385A were constructed as previously
mentioned (Xu, Shi et al. 2002).
siRNA treatment
Both siRNAs and delivery reagent were purchased from Life Technologies
(Carlsbad, CA), and treatment of cells with siRNAs was carried out according to
the manufacturer’s instruction.
Immunoprecipitation (IP)
Protein A sepharose was purchased from Pharmacia Biotech (Piscataway, NJ).
After transfection for 24 hours, cells were collected with 1% Chapso buffer
(20mM Tris pH 8.0, 150mM NaCl, 5mM EDTA and cocktail). Chapso was
phurchased from Amresco (Solon, OH). The collected samples were then
immunoprecipitated with varied antibodies (check figure for details) overnight at 4
℃ in the presence of Protein A conjugated beads. After immunoprecipitation,
samples were washed and analyzed through western blotting.
SDS-PAGE and Western blotting
For the analysis of the activity of gamma secretase, gamma secretase inhibitor
compE (5nM) was applied. For analysis of the exogenous APP and Notch
processing through different PS1C and PS1N terminals, the cells, 24 h after
splitting, were transfected with plasmids expressing NotchΔE with lipofectamine
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LTX. Twelve hours after the transfection of NotchΔE, PS1N and PS1C terminals
were transfected and the cells were further incubated for about 24 hours. Cell
lysis and Western blot analysis were carried out as described previously (Zhao,
Mao et al. 2004), which is consistent to which described briefly in last chapter.
The membranes were probed with appropriate antibodies as described in figure
legends.

Results
Two aspartyl acids on PS1 were essential for the processing of Notch
The two conserved aspartic acid residues at positions 257 and 385 in PS1 have
been identified as the catalytic residues in -secretase by a pioneer study (Wolfe
1999), and the hypothesis that these residues form the active site for the secretase enzyme complex has been well supported (Steiner, Duff et al. 1999,
Kimberly, Xia et al. 2000). Our results presented in the previous chapter
demonstrated that -secretase catalyzed processing of Notch was achieved by
transfection of PS1 and PS2 double knockout (PS1/2-/-) cells with PS1N in
combination with PS1C of different length. It is noted that all the PS1Cs
[PS1C293(aa293-aa467), PS1C296(aa296-aa467), PS1C299(aa299-aa467),
PS1C334(a334-aa467), and PS1C346(aa346-aa467)] examined bear the aspartyl
residue 385 (D385), indicating that as long as the PS1C contains the D385
residue, regardless of difference in length, it is capable of to forming a functional
heterodimer with PS1N (aa1 to aa292), which bears the aspartyl residue 257
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(D257), to process Notch. To test this speculation that these two aspartyl
residues essential for PS1 function under our experimental conditions, I
transfected PS1 plasmid and three mutant PS1: PS1D385A, PS1D257A, and
PS1D257A/D385A

along with NotchE back into PS1/2-/- cell. As shown in Figure 3.1,

as detected with -myc, NotchΔE, which is expressed with a myc-tag at its Cterminal, was found expressed equally in all the transfectants, except in cells
transfected with NotchE alone (lane 2). However, NICD, the C-terminal
fragment produced form NotchE by -secretase activity, was only detected in
cells expressing PS1wt (lane 4), but not in cells expressing any of these mutant
PS1 mutant (lanes 5-7). As shown in the third panel, significant amounts of PS1,
either PS1wt (lane 4) or mutant PS1 (lanes 5-7), were detected with antibody
5643, which is specific to C-terminal of PS1. Specifically, mutant PS1D385A and
PS1D257A/D385A were expressed at relatively high levels. Thus, the presence or
absence of NICD in cells expressing PS1wt or mutant PS1 is unlikely due to
inefficient expression levels of these PS1 variants. This result confirmed that the
two aspartates are indeed essential for -secretase catalyzed Notch processing.
Pen-2 is directly required for Notch processing through -secretase.
As shown in figure 2.7, co-expression of PS1N and PS1C fragments, containing
these two aspartates separately, was able to process Notch in PS1/2-/- cells.
Pen-2 has been regarded as a necessary factor for endoproteolysis of PS1
required for maturation and activation of -secretase complex by previous studies
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(Luo, Wang et al. 2003, Takasugi 2003). This notion raises a question as to
whether Pen-2 is merely required for endoproteolysis and stabilization of PS1. If
that is the case, co-expression of PS1N and PS1C together may reconstitute secretase activity in the absence of Pen-2. To test this possibility, I transfected
Pen-2-/- cells with PS1wt alone with NotchE or PS1N and PS1C alone with
NotchE. As shown in figure 3.2, all PS1Cs, except PS1C293, were expressed at
substantial levels. Specifically, a significant amount of PS1C (lane 4) was
detected in PS1wt-transfected cells and this result further confirmed out previous
finding that Pen-2 is not absolutely required for PS1 endoproteolytic processing
(Mao, Cui et al. 2012). Interestingly, despite the presence of significant amount of
PS1C and PS1N, no Notch processing product NICD was detected in PS1wt or
PS1N/PS1C transfected cells. This result indicates that in addition of enhancing
PS1 endoproteolytic processing and stabilization of PS1, Pen-2 is directly
required for the catalytic activity of  secretase.
Knockdown of NCT in Aph-1-/- cells does not affect the Notch processing.
Data presented in chapter 1 demonstrated that knockout of Aph-1 or NCT
separately does not affect the processing of Notch. However, it is not known
whether as long as either one of Aph-1 or NCT presences will be sufficient to
support the -secretase activity or both Aph-1 and NCT are not required for secretase catalyzed Notch processing. To address this issue, using the siRNA
approach, I determined the effect of knockdown of NCT in Aph-1-/- cells on the
processing of Notch. As shown in figure 3.3, knockdown of NCT was achieved by
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all three siRNAs used (lanes 3-5, third panel). In addition, transient expression of
NotchE was detected at fair equal levels in all the transfected cells. Surprisingly,
NICD was detected in all the cells (lanes 1-5). This result strongly suggests that
both Aph-1 and NCT are dispensable for Notch processing. In another word,
Pen-2 and PS1 are sufficient for the activity of  secretase to process Notch.
The association of PS1N and PS1C was not disturbed by the deletion of
Pen-2.
It is well established that PS1 is the catalytic component (De Strooper, Saftig et
al. 1998); however the role of Pen-2 in -secretase remains elusive. The data
presented above strongly suggest that Pen-2 is directly involved in -secretase
activity. This finding prompts us to further investigate the mechanism by which
Pen-2 is involved in -secretase activity. One possibility is that Pen-2 might be
required for enhancing and stabilizing the PS1N/PS1C heterodimer formation. To
test this possibility. I examined the effect of knockout of Pen-2 on the formation of
PS1N/PS1C heterodimer. To do so, I transfected Pen-2-/- cells and PS1/2-/- cells
with both PS1N and PS1C and performed co-immunoprecipitation on these cell
lysates. As shown in figure 3.4, we found that PS1N could pull down varied
PS1C in PS1/2-/- (bottom panel). This result confirmed that in PS1N and PS1C
are capable of forming dimer in the absence of Pen-2. The data presented in
figure 3.4 also demonstrated that PS1N is not only capable of forming complex
with PS1Cs produced by normal endoproteolytic processing, such as PS1C293,
PS1C296, and PS1C299 (lanes 4, 5, and 6), but also capable of forming complex
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with the PS1Cs produced by caspase activity, such as PS1C334 and PS1C346
(lanes 7 and 8). Since overexpression of PS1wt could induce apoptosis (Zeng,
Hu et al. 2015), thus, the apoptotic PS1C346 was detected in cells transfected
with PS1wt (lane 3). It should be noted that, because they run at the similar
migration rate, the regular PS1C293, PS1C296, PS1C299 could not be distinguished
from IgG light chain. These data clearly indicate that Pen-2 is not required for the
PS1N/PS1C heterodimer formation.
Pen-2 is required for Notch binding to PS1.
Presenilin is the catalytic component in -secretase complex. The
endoproteolysis of PS and the association of PS1N and PS1C were believed to
be the key in -secretase activity. However, the deletion of Pen-2 did not affect
the association of PS1N and PS1C, suggesting that Pen-2 might participate in
the -secretase activity directly rather than indirectly through regulation of the
formation and stability of the complex of PS1N and PS1C. Thus, the other
possibility is that Pen-2 might play an important role in recruiting Notch. In order
to test our hypothesis, I performed the following experiments.
First, all the cells were transfected with NotchΔE alone with either empty
vector or plasmids expressing PS1 variants. In WT cells, certain level of Notch
was co-immunoprecipitated with Pen-2 by anti-Pen-2 antibody (lane 10, upper
top panel). However, PS1C antibody hardly pull down any Notch (lane 11). This
is likely due to the activity of -secretase that processes NotchE into NICD,
which is no longer associated with PS1. Therefore, I cultured WT cells in the
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presence of -secretase inhibitor Compoud E, which could partially block the
processing of Notch. Indeed, Notch was pulled down by PS1C antibody in WT
cells in the presence of compound E (lane 14, top panel). However, it was also
noted that the level of Notch pulled down by Pen-2 antibody was more than that
pulled down by PS1C antibody (compare lane 13 with 14), suggesting that the
association between Pen-2 and Notch may be stronger than PS1 with Notch.
To further determine the affinity of Pen-2 and PS1 for Notch, I performed the
co-immunoprecipitation in Pen-2-knockout cells and PS1/2-double knockout
cells. As a result, certain amount of NotchE was co-immunoprecipitated with
Pen-2 in PS1/2-/- cells (lane 1, top panel). However, anti-PS1C antibody did not
bring down any Notch in Pen-2 knockout cells (data not shown). Because PS1 is
very unstable in Pen-2-/- cells, thus, this could be due to the low level of PS1 in
Pen-2-/- cells. Therefore, I performed co-immunoprecipitation in Pen-2-/- cells
transfected with PS1wt and it was found that only a negligible amount of
NotchE was immunoprecipitated by anti-PS1C antibody in Pen-2-/- cells
transfected with both PS1wt and NotchE, (lane 17, top panel). Again, this may
be because of inefficient endoproteolytic processing of PS1 in the absence of
Pen-2. Thus, I transfected Pen-2-/- cells with PS1N and PS1C, which have been
shown to form active -secretase complex and process Notch in PS1/2-/- cells
(figure 2.7). As a result, despite the fact that significant level of PS1C was
detected in these cells (lane 5, third panel), no NotchE was coimmunoprecipitated with PS1C (lane 5, top panel). These results revealed an
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interesting finding that Pen-2 could interact with Notch in the absence of
presenilin, however, presenilin could not interact with Notch in the absence of
Pen-2, suggesting that presenilin interacts with Notch is mediated or enhanced
by Pen-2. It was also noted that in the presence of overexpressed PS1, either
PS1wt or PS1C, not only anti-PS1C antibody but also anti-Pen-2 antibody
brought down more NotchE than in cells without overexpression of PS1
(compare lanes 8 and 20 with lanes 11 and 14 for anti-PS1C antibody and
compare lanes 7 and 19 with lanes 10 and 13 for anti-Pen-2 antibody). These
results indicate that PS1 also enhances the interaction between Pen-2 and
Notch. In addition, this set of experiments further confirmed that Notch is not
processed in the absence of Pen-2 even in the presence of overexpressed PS1
(lanes 6 and 18, second panel). It should be pointed out that the binds detected
by NICD-specific antibody in anti-Pen-2 immunoprecipitated samples (lanes 1, 4,
7, 10, 13, 16, and 19, second panel) are non-specific signals. It was also noted
that in WT cells, anti-myc antibody could bring down PS1C (lanes 12 and 15,
third panel), but not Pen-2 (lane 12 and 15, bottom panel). Also, in WT cells, antiPS1C antibody could bring down Pen-2 (lanes 11 and 14, bottom panel), but not
in PS1/2-/- cells expressing PS1N and PS1C (lanes 8 and 20, bottom panel).

Discussion
Among the four components of -secretase complex, Pen-2 is the relatively less
characterized member. Studies have suggested that Pen-2 plays a role in
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presenilin endoproteolysis and stabilization and nicastrin maturation (Mao, Cui et
al. 2012). Using knockout mouse model, a study hypothesized that Pen-2 is more
than a structural component of the -secretase complex and may contribute to
the catalytic mechanism of the enzyme (Bammens, Chávez-Gutiérrez et al.
2011). In the study presented in this chapter, we used specific knockout cells in
combination with siRNA technology to determine the role of Pen-2 in -secretase
and the mechanism by which Pen-2 contribute to -secretase activity. The most
interesting finding is that knockdown of NCT in Aph-1-/- cells had no significant
effect on Notch processing. In chapter I, our data showed that knockout of either
one of NCT and Aph-1 individually did not impair the enzymatic function of secretase to process Notch. This finding suggests a possibility that the presence
of both of NCT and Aph-1 simultaneously is not required for Notch processing. In
other words, either NCT or Aph-1 along with Pen-2 and PS1 will form a functional
complex to process Notch. However, data presented in this chapter surprisingly
demonstrated that the knockdown of NCT in Aph-1-/- cells had no significant
effect on Notch processing. This finding strongly suggests that Pen-2 and PS1
are the minimal required and sufficient to catalyze Notch processing. To further
investigate the mechanism by which Pen-2 plays a directly role in Notch
processing, our data revealed that Notch could not be co-immunoprecipitated
with Pen-2 in PS1/2-/- double knockout cells, however, Notch was coimmunoprecipitated with PS1 in Pen-2-/- cells. This result indicates that Notch
interacts with Pen-2 in the absence of PS1, but PS1 can’t interact with Notch in
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the absence of Pen-2. This finding strongly suggests a possibility that interaction
between PS1 and Notch is mediated by Pen-2, i.e., Pen-2 functions as a receptor
in recruiting substrate to -secretase complex. These novel findings revealed a
important function of Pen-2 and will greatly contribute to our understanding of the
molecular mechanism of -secretase activity.
In addition, the data presented in this chapter lead to several interesting findings.
First, using the PS1/2-/- double knockout cells, our data clearly demonstrated
that introduction of the PS1D257A and PS1D2385A point mutations in PS1 result in
an inactive -secretase for processing Notch and this finding confirmed again that
these two aspartyl residues are essential for -secretase activity as reported by
previous study (Wolfe, Xia et al. 1999).
Second, our data demonstrated that all the PS1 C-terminal fragments
produced during endoproteolysis and by caspase activity are functional in Notch
processing when expressed along with PS1N. it has been reported that during
maturation, PS1 undergoes endoproteolytic processing and the produced PS1N
and PS1C fragments form heterodimer. Study also reported that, similar to APP,
endoproteolysis of PS1 also follows a stepwise sequential cleavage and result in
the formation of PS1Cs of different length of which PS1C299 is the major species
(Fukumori, Fluhrer et al. 2010). Our data showed that co-expression of the
PS1Cs with different length corresponding to the PS1Cs produced during
endoproteolysis and by caspase activity along with PS1N resulted in Notch
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processing. These results indicate that all these PS1Cs are functional in
constituting active -secretase.
Third, Pen-2 is not required for PS1N and PS1C heterodimer formation. It has
been concerned that the heterodimer of PS1N and PS1C might been disturbed in
the absence of Pen-2 (reference is missing). However, the immunoprecipitation
results demonstrated that the association of PS1N and PS1C were not affect by
the deletion of Pen-2. Our finding is also supported by a previous study showing
that Pen-2 did not enhance the level of heterodimer of PS1 (Shiraishi, Sai et al.
2004). Combined together, it is clearly indicated that Pen-2 is directly involved in
 secretase activity rather than indirectly by enhancing PS1N/PS1C heterodimer
formation.
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Figure 3.1
Figure 3.1 Two aspartyl acids on PS1 were essential for the processing of Notch.
Notch was overexpressed in PS1/2-/- cell with the transfection of NotchΔE and
detected with -myc in the first panel. The processing of Notch was detected in
the second panel with antibody C-Notch. Cells were also transfected with PS1
WT and PS1 mutants: PS1D257A, PS1D385A and PS1D257,385A, the expression of
PS1 and PS1 mutants were reflected with antibody PS1C 5643. GAPDH was
applied as loading control as shown in the bottom panel.
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Figure 3.2
Figure 3.2 Pen-2 is directly required for Notch processing through -secretase.
NotchΔE could not be processed by the double transfection of PS1C terminal
fragments (all the truncated PS1 Cs) and PS1N fragments in Pen-2-/- cell. Pen-2
knockout cells was transfected with different PS1 C terminals and PS1N
terminals together with NotchΔE. And immunoblot probed with anti PS1C
antibody 5643, -myc, c-Notch and GAPDH separately.
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Figure 3.3
Figure 3.3 Knockdown of NCT in Aph-1-/- cell does not affect the Notch
processing. NotchΔE was overexpressed in Aph-1-/- cell and detected with -myc
(first panel). PS1/2-/- and wt cell were used as control. Three NCT siRNA
reagents (1,2 and 3) were applied and the knockdown results were detected in
the third panel with antibody NCT. The processing of Notch was detected in the
second panel with antibody C-Notch. GAPDH was applied as loading control as
shown in the bottom panel.
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Figure 3.4
Figure 3.4 The association of PS1N and PS1C was not disturbed by the deletion
of Pen-2. PS1N and varied PS1Cs (PS1C293, PS1C296, PS1C299, PS1C334,
PS1C346) were transfected into Pen-2-/- and PS1/2-/- cell. WT cell and Wt-7 cell
were used as control. Samples were immunoprecipitated with antibody PS1N
and the association of PS1N and PS1C were indicated with the detection of PS1
by the antibody PS1C 5643 (shown in the two panels).
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Figure 3.5
Figure 3.5 Pen-2 is required for Notch binding to PS1.Notch ΔE were transfected
into Pen-2-/- , PS1/2-/- and WT cell and the expression were detected in the first
row with -myc antibody. PS1WT plasmids and PS1C299, PS1N were transfected
into Pen-2-/- and PS1/2-/- cell and detected with antibody 5643 in the third row.
The processing of Notch was detected with antibody C-Notch in the second row.
The level of Pen-2 was detected in bottom row with anti-Pen-2 antibody. All the
samples were immunoprecipitated with varied antibodies: Pen-2, PS1C 5643 and
-myc as indicated in the figure. As secretase inhibitor, CompE (5nM) was
applied in WT cell.
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CONCLUSION
Since -secretase is the key enzyme in A production, it has attracted particular
attention in Alzheimer’s disease research. However, despite of numerous studies
that have focused on the structure and function of -secretase complex, there are
still a lot of questions remaining to be answered regarding the biological function
and specific role of each component in the -secretase complex. My study is
mainly focused on the role of each secretase components in its activity and
stability of the complex.
In conclusion, the first finding of my research is that Aph-1 is dispensable for
secretase activity of processing both APP and Notch.
Second, our data revealed a very interesting finding that NCT is required for
processing of APP, while it is not necessary for the processing of Notch. Even
though the molecular mechanism of this finding needs to be further investigated,
it opens a new avenue for searching for target of blocking production of
Awithout affecting the signal transduction of NICD.
Third and most importantly, our data revealed that Pen-2 and PS1 are the
minimal required and essential components for constituting active secretase of
processing Notch. As a mechanism, our data uncovered a novel function of Pen2 in binding and recruiting substrate Notch to secretase.
In addition, our data also demonstrated that knockout of Aph-1 sensitizes cells
to apoptotic stimuli.
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